Sopharma AD

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

"Sopharma" AD (the Company) notifies that for July 2020 the Company recorded a decrease in sales of 52% compared to the same month of 2019, incl. 25% decrease in domestic sales and 66% decrease in export sales.

In the first seven months of 2020 the revenues from sales of production decrease by 6% compared to the same period of 2019, incl. 20% decrease of sales for the domestic market and 2% increase in export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 24, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sofia, Bulgaria, June 25, 2020 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on June 24, 2020 the Company sold 5 000 own shares representing 0.0037% of the share capital of the Company, at a total value of BGN 15 750 on the Bulgarian Stock Exchange, the average price per share was 3.1500 BGN.

The total number of treasury shares after this transaction is 9 053 467, representing 6.716% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 24, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 23, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 22, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 23, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sofia, Bulgaria, June 23, 2020 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on June 22, 2020 the Company sold 25 000 own shares representing 0.0185% of the share capital of the Company, at a total value of BGN 78 750 on the Bulgarian Stock Exchange, the average price per share was 3.1500 BGN.

The total number of treasury shares after this transaction is 9 058 467, representing 6.720% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 22, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 19, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sofia, Bulgaria, June 22, 2020 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on June 19, 2020 the Company sold 6 000 own shares representing 0.0045% of the share capital of the Company, at a total value of BGN 18 870 on the Bulgarian Stock Exchange, the average price per share was 3.1450 BGN.

The total number of treasury shares after this transaction is 9 083 467, representing 6.739% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 19, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 18, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sofia, Bulgaria, June 19, 2020 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) ) notifies that on June 18, 2020 the Company sold 4 000 own shares representing 0.0030% of the share capital of the Company, at a total value of BGN 12 540 on the Bulgarian Stock Exchange, the average price per share was 3.1350 BGN.

The total number of treasury shares after this transaction is 9 089 467, representing 6.743% of the share capital of the Company

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 17, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sofia, Bulgaria, June 19, 2020 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on June 17, 2020 the Company sold 21 000 own shares representing 0.0156% of the share capital of the Company, at a total value of 68 030 BGN on the Bulgarian Stock Exchange, the average price per share was 3.2395 BGN.

The total number of treasury shares after this transaction is 9 093 467, representing 6.746% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 17, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sofia, Bulgaria, June 18, 2020 - According to the requirements of art. 111, para. 8 of LPOS "Sopharma" AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that due to a technical error in the Notification for treasury shares, number 194-00-31 / 16.06.2020 should be read:

"Sofia, Bulgaria, June 16, 2020 - According to the requirements of art. 111, para. 8 of LPOS "Sopharma" AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on June 15, 2020 the Company sold 85 748 own shares representing 0.0636% of the share capital of the Company, at a total value of 277 823,52 BGN on the Bulgarian Stock Exchange, the average price per share was 3.240 BGN.

The total number of treasury shares after this transaction is 9 114 467, representing 6.762% of the share capital of the Company."

We apologize for the inconvenience.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 16, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 15, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

"Sopharma" AD (the Company) notifies that to improve the operational management of the Company the Board of Directors assigned Mr. Simeon Donev, Director Business Development of "Sopharma" AD as a procurator.

The change was announced by the Commercial Register, Registry agency with number 20200616134043 from June 16, 2020.

Mr. Donev has nearly 5 years of experience in areas as international projects, commerce, marketing and strategic planning. For more than 3 years Mr. Donev leads the Business Development tam and has a number of successful projects behind him.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on June 15, 2020 the Company bought 85 748 own shares representing 0.0636% of the share capital of the Company, at a total value of 277 823,52 BGN on the Bulgarian Stock Exchange, the average price per share was 3.240 BGN.

The total number of treasury shares after this transaction is 9 285 963, representing 6.89% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 15, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 12, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 12, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 11, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 11, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 10, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 9, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 8, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 5, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 8, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 4, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Minutes of the Annual General Meeting of Shareholders of Sopharma AD, held on 5 June 2020

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

"Sopharma" AD (the Company) notifies that for May 2020 the Company recorded a decrease in sales of 6% compared to the same month of 2019, incl. 9% decrease in domestic sales and 5% decrease in export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 3, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 3, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 2, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of June 2, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 2, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

"Sopharma" AD notifies that on June 1, 2020 the Company bought 86 748 own shares representing 0.0644% of the share capital of the Company, at a total value of 260 244 BGN on the Bulgarian Stock Exchange, the average price per share was 3.00 BGN.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of June 1, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Consolidated Financial Report as at 31 March 2020

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

"Sopharma" AD invites all shareholders of the Company to exercise their voting right on the announced agenda items of the Annual General Meeting convened for 5 June 2020 through correspondence. In an effort to preserve the normal operation of all the bodies of "Sopharma" AD and at the same time not to jeopardize the health of the interested parties in the conditions of a pandemic, the Board of Directors provide an opportunity for shareholders to exercise their voting rights in advance. On the day of the General Meeting the Company will hold an online meeting with Ognyan Donev, PhD, Executive Director and Chairman of the Board of Directors of "Sopharma" AD, Dimitar Dimitrov, Executive Director of "Sopharma Trading" AD and Alexander Hristov, Executive Director of "Doverie Obedinen Holding" AD.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sales revenues for April 2020

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Publication of materials for holding a Regular General Meeting of Shareholders of "Sopharma" AD, scheduled for 5 June 2020

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Consolidated Audited Financial Report according to IFRS as at 31 December 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sofia, Bulgaria, April 6, 2020 - "Sopharma" AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that the Consolidated Audited Financial Statements for 2019 will be made public in the terms envisaged in §45, item 2 of the TAP of the Law for the measures and actions under extraordinary circumstances. The delayed publishing of the Report is due to the extraordinary conditions in a number of countries in which the companies from the Group operate. Measures have been taken within the Company to decrease to a maximum the timeframe for finalizing and publishing of all documents part of the Report.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Q1 2020 Individual Financial report of Sopharma AD

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Telso AD under Art. 19 of Regulation (EU) No 596/2014 of April 3, 2020.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

"Sopharma" AD (the "Company") notifies that for March 2020 the Company recorded an increase in sales of 11% compared to the same month of 2019, incl. fulfillment of sales for the domestic market and 21% increase in export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Annual Audited Individual Financial Statements for 2019 of Sopharma AD:

Individual Audited Financial Report according to IFRS as at 31 December 2019

Notes to the Individual Audited financial report as at 31 December 2019

Management report as at 31 December 2019

Individual Audited Financial Report according to BFSC standards as at 31 December 2019

Auditor's declaration as at 31 December 2019

Auditor's report as at 31 December 2019

Corporate Governance Declaration as at 31 December 2019

Report regarding the application of the remuneration policy as at 31 December 2019

Declaration by responsible directors as at 31 December 2019

Non-financial Declaration to the Annual Financial Report as at 31 December 2019

Individual Audited Financial Report according to IFRS as at 31 December 2019 - xls

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (the "Company") notifies that for February 2020 the Company recorded a decrease in sales of 22% compared to the same month of 2019, incl. 1% decrease in sales for the domestic market and 30% decrease in export sales.

In the first two months of 2020 the revenues from sales of production decreased by 15% compared to the same period of 2019, incl. 2% decrease in domestic sales and 20% increase in export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Consolidated financial report according to IFRS as at 31 December 2019

Notes to the consolidated financial report as at 31 December 2019

Consolidated management report as at 31 December 2019

Insider information as at 31 December 2019

Additional information as at 31 December 2019

Consolidated financial report according to BFSC standards as at 31 December 2019

Information according to Annex 9 of Ordinance 2 as at 31 December 2019

Declaration by the responsible directors as at 31 December 2019

Consolidated financial report according to IFRS as at 31 December 2019 - Excel

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (the "Company") notifies that for January 2020 the Company recorded a decrease in sales of 8% compared to the same month of 2019, incl. 2% decrease in sales for the domestic market and 10% decrease in export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Q4 2019 Individual Financial report of Sopharma AD:

Individual financial report according to IFRS as at 31 December 2019

Notes to the individual financial report as at 31 December 2019

Management report as at 31 December 2019

Insider information as at 31 December 2019

Additional information as at 31 December 2019

Individual financial report according to BFSC standards as at 31 December 2019

Information according to Annex 9 of Ordinance 2 as at 31 December 2019

Declaration by the responsible directors as at 31 December 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that the Company will initiate gross dividend payment of the voted on the EGM held on December 13, 2019 dividend of 0.05 BGN per share on January 22, 2020.

The persons eligible for dividend are those present in the register of the Central Depository 14 days after the date of the AGM, i.e. December 27, 2019.

In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Postbank in the country until April 30, 2020 (after that date, shareholders who have not received their dividend in the appropriate order may do that at the cash desk of the Company in Sofia, 16 Iliensko Shose Str. every business day between 10:00-12:00 and 14:00-16:00, tel. 02 8134 283).

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (the "Company") notifies that for December 2019 the Company recorded an increase in sales of 16% compared to the same month of 2018, incl. 5% increase in sales for the domestic market and 27% increase in export sales.

In 2019 the revenues from sales of production increased by 9% compared to the same period of 2018, incl. keeping sales in domestic market and 15% increase in export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 30, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 27, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 23, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 20, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on December 20, 2019 the Company bought 800 own shares representing 0.0006% of the share capital of the Company, at a total value of 2 760 BGN on the Bulgarian Stock Exchange, the average price per share was 3.4500 BGN.

The total number of treasury shares after this transaction is 9 113 467, representing 6.761% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 19, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 18, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sofia, Bulgaria, December 20, 2019 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 19, 2019 the Company bought 2 000 own shares representing 0.0015% of the share capital of the Company, at a total value of 6 890 BGN on the Bulgarian Stock Exchange, the average price per share was 3.4450 BGN.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 19, 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 18, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 17, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sofia, Bulgaria, December 18, 2019 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 17, 2019 the Company bought 28 390 own shares representing 0.0211% of the share capital of the Company, at a total value of 98 346,20 BGN on the Bulgarian Stock Exchange, the average price per share was 3.4641 BGN.

The total number of treasury shares after this transaction is 9 110 667, representing 6.76% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 17, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sofia, Bulgaria, December 17, 2019 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) - Please apologize us for the following technical errors:

- In the Notification for treasury shares, published on December 11, 2019, please read the total number of treasury shares "8 906 832", instead of "8 904 182".

- In the Notification for treasury shares, published on December 13, 2019, please read number of shares "46 320", instead of "41 320" and the total number of treasury shares "9 037 320", instead of "9 032 320".

- In the Notification for treasury shares, published on December 16, 2019, please read the text "Тhe Company bought 14 760 own shares representing 0.0109% of the share capital of the Company, at a total value of 50 922 BGN on the Bulgarian Stock Exchange, the average price per share was 3.45 BGN. The total number of treasury shares after this transaction is 9 052 080, representing 6.715% of the share capital of the Company" ,instead of "Тhe Company bought 46 320 own shares representing 0.0344% of the share capital of the Company, at a total value of 159 693,26 BGN on the Bulgarian Stock Exchange, the average price per share was 3.4476 BGN. The total number of treasury shares after this transaction is 9 078 640, representing 6.74% of the share capital of the Company".

- In the Notification for treasury shares, published on December 17, 2019, please read the total number of treasury shares "9 082 277" representing 6.738% of the share capital of the Company, instead of "9 108 837" representing 6.76% of the share capital of the Company.

We apologize for the inconvenience.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on December 16, 2019 the Company bought 30 197 own shares representing 0.0224% of the share capital of the Company, at a total value of 104 381,63 BGN on the Bulgarian Stock Exchange, the average price per share was 3.4567 BGN.

The total number of treasury shares after this transaction is 9 108 837, representing 6.76% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 16, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sofia, Bulgaria, December 16, 2019 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 13, 2019 the Company bought 46 320 own shares representing 0.0344% of the share capital of the Company, at a total value of 159 693,26 BGN on the Bulgarian Stock Exchange, the average price per share was 3.4476 BGN.

The total number of treasury shares after this transaction is 9 078 640, representing 6.74% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Minutes from a Extraordinary General meeting of shareholders of Sopharma AD

Protocol of the Commission for Verification of the Quorum for the Extraordinary General meeting of shareholders of Sopharma AD

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sofia, Bulgaria, December 16, 2019 - Sopharma AD notifies that due to a technical error in the Notification for treasury shares, published on December 13, 2019, please read the sum of the total value of treasury shares "BGN 142 442,436", instead of "BGN 412 443,26".

We apologize for the inconvenience.

Please, on the grounds of Art. 100k, para. 1 of the POSA make the above information public.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on December 12, 2019 the Company bought 41 320 own shares representing 0.0307% of the share capital of the Company, at a total value of 412 443,26 BGN on the Bulgarian Stock Exchange, the average price per share was 3.4473 BGN.

The total number of treasury shares after this transaction is 9 032 320, representing 6.70% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 12, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 12, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Telso AD under Art. 19 of Regulation (EU) No 596/2014 of December 10, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

In accordance with Art. 115c, para. 4 of the Public Offering of Securities Act Sopharma AD hereby notifies all shareholders of the Company about the decision of the EGM of Sopharma AD that took place on December 13, 2019 regarding the amount and type of dividend distributed and the terms and conditions for its distribution:

AGM approves the proposal by the Board of Directors for the distribution of 6 - month dividend at the amount of 0.05 BGN /five stotinki/ per share with dividend right.

The persons eligible for dividend are those present in the register of the Central Depository 14 days after the day of the AGM on which the 6 - Month Financial Report was approved and the decision for dividend was taken, namely December 27, 2019 (record date) - ex dividend date December 23, 2019.

In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country.

We would like to thank all shareholders for their understanding and cooperation.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 11, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sofia, Bulgaria, December 12, 2019 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 11, 2019 the Company bought 84 168 own shares representing 0.0624% of the share capital of the Company, at a total value of 290 379,60 BGN on the Bulgarian Stock Exchange, the average price per share was 3.45 BGN.

The total number of treasury shares after this transaction is 8 991 000, representing 6.67% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 11, 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on December 10, 2019 the Company bought 25 000 own shares representing 0.0185% of the share capital of the Company, at a total value of 85 800 BGN on the Bulgarian Stock Exchange, the average price per share was 3.432 BGN.

The total number of treasury shares after this transaction is 8 904 182, representing 6.61% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 10, 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 9, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 9, 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 6, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 5, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 6, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 5, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (the "Company") that for November 2019 the Company recorded an increase in sales of 24% compared to the same month of 2018, incl. 21% increase in sales for the domestic market and 27% increase in export sales.

In the first eleven months of 2019 the revenues from sales of production increased by 8% compared to the same period of 2018, incl. 1% decrease in domestic sales and 14% increase in export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 4, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 3, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of December 3, 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 3, 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of December 2, 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Consolidated financial report according to IFRS as at 30 September 2019

Notes to the consolidated financial report as at 30 September 2019

Consolidated management report as at 30 September 2019

Insider information as at 30 September 2019

Additional information as at 30 September 2019

Consolidated financial report according to BFSC standards as at 30 September 2019

Information according to Annex 9 of Ordinance 2 as at 30 September 2019

Declaration by the responsible directors as at 30 September 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on 12 November, with the participation of His Excellency Evgueni Stoytchev, the Ambassador of the Republic of Bulgaria in Moldova, Sopharma AD celebrated the opening of a new warehouse and administrative building in Kishinev with a total area of 5000 sq. m. The warehouse will provide 75 new working places and will support the distribution activities of pharmaceutical and other health related products of Sopharma AD in Moldova, further the centralization will lead to improved efficiency and optimization of the processes.

Following its intentions to grow in Moldova, Sopharma AD purchased 29% of the capital of RAP Pharma International and reached 80% ownership in the company. RAP Pharma International also has a new Executive director Mr. Victor Tomsha - a young specialist with economic education and professional experience in large European companies.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Za pierwsze półrocze 2018 roku spółka również wypłaciła 0,05 BGN dywidendy na akcję. (PAP Biznes)

doa/ osz/

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Invitation and materials for an Extraordinary General Meeting of Shareholders of Sopharma AD for 13 December 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for October 2019 the Company recorded an increase in sales of 40% compared to the same month of 2018, incl. 30% increase in sales for the domestic market and 48% increase in export sales.

In the first ten months of 2019 the revenues from sales of production increased by 6% compared to the same period of 2018, incl. 4% decrease in domestic sales and 13% increase in export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Individual financial report according to IFRS as at 30 September 2019

Notes to the individual financial report as at 30 September 2019

Management report as at 30 September 2019

Insider information as at 30 September 2019

Additional information as at 30 September 2019

Individual financial report according to BFSC standards as at 30 September 2019

Information according to Annex 9 of Ordinance 2 as at 30 September 2019

Declaration by the responsible directors as at 30 September 2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (the "Company") notifies that for September 2019 the Company recorded an increase in sales of 31% compared to the same month of 2018, incl. 5% decrease in sales for the domestic market and 66% increase in export sales.

In the first nine months of 2019 the revenues from sales of production increased by 2% compared to the same period of 2018, incl. 9% decrease in domestic sales and 10% increase in export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Rositsa Doneva in accordance with article 19 of Regulation 596/2014 for transactions from 30 September 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev investments holding AD according to art. 19 of Regulation 596/2014 for transactions from 30.09.2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev investments holding AD according to art. 19 of Regulation 596/2014 for transactions from 30.09.2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 30 September 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on September 26, 2019 the Company bought 182 own shares representing 0.0001% of the share capital of the Company, at a total value of 607.88 BGN on the Bulgarian Stock Exchange, the average price per share was 3.34 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.

The total number of treasury shares after this transaction is 8 881 832, representing 6.59% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Rositsa Doneva in accordance with article 19 of Regulation 596/2014 for transactions from 25 September 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev investments holding AD according to art. 19 of Regulation 596/2014 for transactions from 16.09.2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 25 September 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 24 September 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev investments holding AD according to art. 19 of Regulation 596/2014 for transactions from 20.09.2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 19 September 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 18 September 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 17 September 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 16 September 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 13 September 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev investments holding AD according to art. 19 of Regulation 596/2014 for transactions from 11.09.2019

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 11 September 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 10 September 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 9 September 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 5 September 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for August 2019 the Company recorded a decrease in sales of 3% compared to the same month of 2018, incl. 2% decrease in sales for the domestic market and 3% decrease in export sales.

In the first eight months of 2019 the revenues from sales of production decreased by 1% compared to the same period of 2018, incl. 9% decrease in domestic sales and 4% increase of export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 4 September 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 3 September 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev in accordance with article 19 of Regulation 596/2014 for transactions from 2 September 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Financial report according to IFRS as at 30 June 2019 - consolidated

Notes to the financial report as at 30 June 2019 - consolidated

Management report as at 30 June 2019 - consolidated

Insider information as at 30 June 2019 - consolidated

Additional information as at 30 June 2019 - consolidated

Financial report according to BFCS standards as at 30 June 2019 - consolidated

Annex 9 as at 30 June 2019 - consolidated

Declaration as at 30 June 2019 - consolidated

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that for the convenience of all shareholders the registration for participation in the Annual General meeting convened for 7 June 2019 will end at 10:45 am in order to allow for timely start of the General meeting.

Please note that for the first year the General meeting will be held at the new Event Center, which is located on the Ground floor of Sopharma Business Towers.

For registration and participation in the AGM, physical persons - shareholders must present an identity document. Legal entities - shareholders must provide an original or a certified copy of a valid commercial/court registration certificate as well as the legal representative's identity document.

For securing the registration procedure for participation in the General meeting of shareholders, copies of the issued powers of attorney should be submitted to the Company in hard copy or in electronic form at the latest by the end of the business day preceding the date of the General meeting, namely 17.00 hours on 6 June 2019.

Sopharma AD will receive and accept valid electronic notices and proxies by e-mail to the following e-mail address: ir@sopharma.bg according to the instructions described in the Invitation for convening the Annual General meeting of shareholders.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Financial report according to IFRS as at 31 March 2019 consolidated

Notes to the financial report as at 31 March 2019 consolidated

Management report as at 31 March 2019 consolidated

Insider information as at 31 March 2019 consolidated

Additional information as at 31 March 2019 consolidated

Financial report according to BFCS standards as at 31 March 2019 consolidated

Annex 9 as at 31 March 2019 consolidated

Declaration of the responsible directors

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

1. Financial report according to IFRS as at 31 December 2018

2. Notes to the financial report as at 31 December 2018

3. Management report as at 31 December 2018

4. Non-financial declaration

5. Corporate governance declaration

6. Financial report according to BFCS standards as at 31 December 2018

7. Remuneration Policy Report

8. Declaration as at 31 December 2018

9. Auditors Report

10. Auditors Declaration

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (the "Company") notifies that for February 2019 the Company recorded a decrease of sales revenues of 14% compared to the same month of 2018, including 38% decrease of domestic sales and an increase of 1% of export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Consolidated preliminary financial statements of Sopharma Group for 2018

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for January 2019 the Company recorded an increase of sales revenues of 1% compared to the same month of 2018, including 15% decrease of domestic sales and an increase of 13% of export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

1. Financial report according to IFRS as at 31 December 2018

2. Notes to the financial report as at 31 December 2018

3. Management report as at 31 December 2018

4. Insider information as at 31 December 2018

5. Additional information as at 31 December 2018

6. Financial report according to BFCS standards as at 31 December 2018

7. Annex 9 as at 31 December 2018

8. Declaration as at 31 December 2018

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD received a a notification for disclosure of a shareholding under Art. 145 of the CUPF Allianz Bulgaria for acquiring shares from the capital of Sopharma AD, as a result of which the shareholding of CUPF Allianz Bulgaria in the capital of Sopharma AD exceeds the limit of 5% and reaches 5.09%.

The date of the registration of the transaction with the Central Depository is January 23, 2019.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for December 2018 the Company recorded an increase of sales revenues of 26% compared to the same month of 2017, including 75% increase of domestic sales and a decrease of 1% of export sales.

In 2018 revenue from sales of goods decreased by 3% compared to the same period in 2017, incl. 3% increase in sales for the domestic market and 7% decrease in export sales.

"It's been a year of review - on our 85th anniversary, we looked back to enjoy our successes, to thank the people with whome we've achieved them and celebrate with everyone we want to share our future with. Thank you for sharing! We are proud to have been among the pioneers with two major initiatives - we have distributed shares to all our employees according to their length of service and contribution to the company's successes and distributed the first interim dividend. We have received support from our shareholders for both initiatives, which has always been an important indication for us confirming that we are doing the right thing.", commented Mr. Ognian Donev, PhD, Executive Director and Chairman of the Board of Directors of Sopharma AD.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on December 28, 2018 the Company bought 314 own shares representing 0.0002% of the share capital of the Company, at a total value of 1 105.28 BGN on the Bulgarian Stock Exchange, the average price per share was 3.52 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.

The total number of treasury shares after this transaction is 8 881 650, representing 6.59% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on December 21, 2018 the Company bought 3 500 own shares representing 0.0026% of the share capital of the Company, at a total value of 12 425.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.55 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.

The total number of treasury shares after this transaction is 8 881 336, representing 6.59% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Telecomplect Invest AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Telecomplect Invest AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Telecomplect Invest AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Telecomplect Invest AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 18, 2018 the Company sold 3 000 own shares representing 0.0022% of the share capital of the Company, at a total value of 10 770.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.59 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.

The total number of treasury shares after this transaction is 8 877 836, representing 6.59% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 17, 2018 the Company bought 17 000 own shares representing 0.0126% of the share capital of the Company, at a total value of 61 200.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.60 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.

The total number of treasury shares after this transaction is 8 880 836, representing 6.59% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 14, 2018 the Company bought 5 000 own shares representing 0.0037% of the share capital of the Company, at a total value of 18 000.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.60 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.

The total number of treasury shares after this transaction is 8 863 836, representing 6.58% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 13, 2018 the Company bought 1 000 own shares representing 0.0007% of the share capital of the Company, at a total value of 3 600.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.60 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.

The total number of treasury shares after this transaction is 8 858 836, representing 6.57% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 13, 2018 as a result of the distribution of bonus shares to employees on the occasion of the 85th Anniversary of Sopharma AD, the Company transferred to its employees 500 own shares representing 0.0004% of the capital of the Company.

The total number of treasury shares after this transfer is 8 857 836, representing 6.57% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ivan Badinski - member of the Board of directors of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 12, 2018 the Company bought 3 000 own shares representing 0.0022% of the share capital of the Company, at a total value of 10 800.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.60 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.

The total number of treasury shares after this transaction is 8 858 336, representing 6.57% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 11, 2018 the Company bought 5 000 own shares representing 0.0037% of the share capital of the Company, at a total value of 18 250.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.65 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.

The total number of treasury shares after this transaction is 8 855 336, representing 6.57% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 11, 2018 the Company bought 5 000 own shares representing 0.0037% of the share capital of the Company, at a total value of 18 250.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.65 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.

The total number of treasury shares after this transaction is 8 855 336, representing 6.57% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on December 10, 2018 the Company bought 5 620 own shares representing 0.0042% of the share capital of the Company, at a total value of 20 792.80 BGN on the Bulgarian Stock Exchange, the average price per share was 3.70 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.

The total number of treasury shares after this transaction is 8 850 336, representing 6.57% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 6, 2018 as a result of the distribution of bonus shares to employees on the occasion of the 85th Anniversary of Sopharma AD, the Company transferred to its employees 550 own shares representing 0.0004% of the capital of the Company.

The total number of treasury shares after this transfer is 8 844 716, representing 6.56% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on December 5, 2018 the Company bought 1 000 own shares representing 0.0007% of the share capital of the Company, at a total value of 3 690.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.69 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.

The total number of treasury shares after this transaction is 8 845 266, representing 6.56% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for November 2018 the Company recorded a decrease of sales revenues of 9% compared to the same month of 2017, including 10% increase of domestic sales and a decrease of 23% of export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 4, 2018 the Company bought 7 000 own shares representing 0.0052% of the share capital of the Company, at a total value of 26 360.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.77 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.

The total number of treasury shares after this transaction is 8 844 266, representing 6.56% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on December 4, 2018 as a result of the distribution of bonus shares to employees on the occasion of the 85th Anniversary of Sopharma AD, the Company transferred to its employees 100 own shares representing 0.0001% of the capital of the Company.

The total number of treasury shares after this transfer is 8 837 266, representing 6.56% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on December 3, 2018 the Company bought 1 000 own shares representing 0.0007% of the share capital of the Company, at a total value of 3 740.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.74 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.

The total number of treasury shares after this transaction is 8 837 366, representing 6.56% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

1.Financial report according to IFRS as at 30 September 2018

2.Notes to the financial report as at 30 September 2018

3.Management report as at 30 September 2018

4.Insider information as at 30 September 2018

5.Additional information as at 30 September 2018

6.Financial report according to BFCS standards as at 30 September 2018

7.Annex 9 as at 30 September 2018

8.Declaration as at 30 September 2018

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) announces that on November 16, 2018 in Sofia, 16, Rozhen Blvd was held an annual meeting with the investors of Sopharma AD and Sopharma Trading AD, which started at 13:30 and ended at 17:00. 62 guests were registered for the meeting.

The meeting started with questions from the investors towards the management of Sopharma AD and Sopharma Trading AD.

Mr. Dimitrov presented the largest logistic center of Sopharma Trading AD which is stretched over an area of 15 000 m2 and the storage area is 10 000 m2. In the center is implemented the automated system for warehouse management and medicine distribution - KNAPP, which has no analogue on the Balkan Peninsula. The modern technology accelerates the processing of customer orders 7 times.

The guests of the meeting had the opportunity to visit the Regional distribution center of Sopharma Trading AD, automated with the KNAPP system.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for October 2018 the Company recorded a decrease of sales revenues of 16% compared to the same month of 2017, including 23% decrease of domestic sales and a decrease of 11% of export sales.

In the ten months of 2018 revenue from sales of goods decreased by 5% compared to the same period in 2017, incl. 5% decrease in sales for the domestic market and 5% decrease in export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on October 31, 2018 as a result of the distribution of bonus shares to employees on the occasion of the 85th Anniversary of Sopharma AD, the Company transferred to its employees 500 own shares representing 0.0004% of the capital of the Company.

The total number of treasury shares after this transfer is 8 836 366, representing 6.56% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

1. Financial report according to IFRS as at 30 September 2018

2. Notes to the financial report as at 30 September 2018

3. Management report as at 30 September 2018

4. Insider information as at 30 September 2018

5. Additional information as at 30 September 2018

6. Financial report according to BFCS standards as at 30 September 2018

7. Annex 9 as at 30 September 2018

8. Declaration as at 30 September 2018

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on October 29, 2018 as a result of the distribution of bonus shares to employees on the occasion of the 85th Anniversary of Sopharma AD, the Company transferred to its employees 9 450 own shares representing 0.070% of the capital of the Company.

The total number of treasury shares after this transfer is 8 836 866, representing 6.56% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on October 22, 2018 as a result of the distribution of bonus shares to employees on the occasion of the 85th Anniversary of Sopharma AD, the Company transferred to its employees 277 400 own shares representing 0.2050% of the capital of the Company.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.

The total number of treasury shares after this transfer is 8 846 316, representing 6.56% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Alexandar Tchaushev - member of the Board of directors of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ivan Badinski - member of the Board of directors of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Palaveev - member of the Board of directors of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Vessela Stoeva - deputy chairperson of the Board of directors of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) announces that yesterday it distributed 277 400 shares to 1 733 employees in compliance with the decision of the General Meeting of Shareholders of June 15, 2018 to distribute bonus shares among the employees of the Company for its 85th anniversary. The procedure involved training of all employees for the respective rights they would have as shareholders in the company. The shares of some employees on maternity / paternity leave or long-term sick leave have not yet been allocated.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) kindly invites you to the Annual Investor Relations Meeting that will take place on November 16, 2018, starting at 13:30 in Sofia, 16, Rozhen Blvd., and will include a meeting with the management of the two companies and a visit to the Regional Distribution Center of Sopharma Trading AD automated with the KNAPP system.

You can apply for participation by filling out the attached registration form and sending it to irevents@sopharma.bg. For further information or assistance, please call 02 8134 319. Please refer to the content of the "Privacy Notice for Direct Marketing of Sopharma AD", which is part of the registration form.

The deadline for registration is November 9, 2018.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that the Company will initiate dividend payment of the voted on the EGM held on September, 14 2018 dividend of 0.05 BGN on October, 22 2018.

The persons eligible for dividend are those present in the register of the Central Depository 14 days after the date of the AGM, i.e. September, 28 2018.

In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (the "Company") notifies that for September 2018 the Company recorded decrease of sales revenues of 7% compared to the same month of 2017, including 55% increase of domestic sales and a decrease of 28% of export sales.

Revenue in the third quarter of 2018 increases compared to the same period in 2017, respectively, by 5%, incl. 10% increase of sales for the domestic market and 2% increase in export sales. Successful work during the quarter contributes to reducing the rate of decline in revenue and for the first nine months of this year, revenues from sales of products decreased by 4% (8% as at 30.06.2018) compared to the same period of 2017, including 1% decrease of domestic sales and 6% decrease of export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on 28 September 2018 the Company bought 10 000 own shares representing 0.0074% of the share capital of the Company, at a total value of 40 910.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.09 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after this transaction is 9 123 716, representing 6.77% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on 25 September 2018 the Company bought 2 947 own shares representing 0.0022% of the share capital of the Company, at a total value of 12 023.76 BGN on the Bulgarian Stock Exchange, the average price per share was 4.08 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after this transaction is 9 113 699, representing 6.76% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on 21 September 2018 the Company bought 3 375 own shares representing 0.0025% of the share capital of the Company, at a total value of 13 770.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.08 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

As a result of the merger of Unipharm AD into Sopharma AD 70 623 shares of the treasury shares of the Company were transferred to the shareholders of Unipharm AD. The total number of treasury shares after this transfer is 9 110 752, representing 6.76% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that in the publication for payment of a cash dividend published in www.x3news.com on September 14, 2018, at 12:53 o'clock there was a technical error. On the fifth line is written "... dividend per share net (only for shareholders - physical persons) - 0.05 (only for shareholders - physical persons) BGN" but read: "... dividend per share net (only for shareholders - physical persons) - 0.0475 (only for shareholders - physical persons) BGN "

We apologize for the inconvenience caused. Again, we note that the net dividend value does not include a 5% withholding tax for physical persons.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on 19 September 2018 the Company bought 13 000 own shares representing 0.0096% of the share capital of the Company, at a total value of 53 350.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.10 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 178 000, representing 6.81% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on 18 September 2018 the Company bought 5 000 own shares representing 0.0037% of the share capital of the Company, at a total value of 20 700.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.14 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 165 000, representing 6.80% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on 17 September 2018 the Company bought 1 690 own shares representing 0.0013% of the share capital of the Company, at a total value of 7 013.50 BGN on the Bulgarian Stock Exchange, the average price per share was 4.15 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 160 000, representing 6.80% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on 13 September 2018 the Company bought 4 000 own shares representing 0.003% of the share capital of the Company, at a total value of 16 600.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.15 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 158 310, representing 6.79% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

The Extraordinary General Meeting of Shareholders of Sopharma AD was held on 14 September 2018, at 11.00 in Sofia, 5 Lachezar Stanchev Str., building B of commercial complex Sopharma Business Towers. It was attended by shareholders and their representatives, as per the annex to the Minutes listing the present shareholders and representatives of shareholders, containing the number of shares present and represented.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Dzień dywidendy to 28 września 2018 roku.

W czerwcu akcjonariusze zdecydowali o przeznaczeniu na dywidendę z zysku osiągniętego w 2017 roku oraz z niepodzielonego zysku z poprzednich lat łącznie 43 mln BGN, co da 0,11 BGN dywidendy na akcję. (PAP Biznes)

sar/ osz/

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

In accordance with Art. 115c, para. 2 of the Public Offering of Securities Act Sopharma AD hereby notifies all shareholders of the Company about the decision of the EGM of Sopharma AD that took place on September 14, 2018 regarding the amount and type of 6-month dividend distributed and the terms and conditions for its distribution:

EGM approves the proposal by the Board of Directors for the distribution of dividend at the amount of 0.05 BGN /five stotinki/ per share with dividend right.

The persons eligible for dividend are those present in the register of the Central Depository 14 days after the day of the EGM on which the 6-Month Financial Report for the first half of 2018 was approved and the decision for dividend was taken, namely the record date: September 28, 2018 (ex-dividend date: September 27, 2018).

In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country.

The company is obligated to pay the dividend within 60 days of the respective GM. The date on which the dividend payment will commence and the total amount of dividend will be announced accordingly.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that the procedure for merger of Unipharm AD into Sopharma AD finished today with an entry in the Commercial register number 20180913171143.

Sopharma AD will take actions to deregister Unipharm AD from the list of public companies and from the BSE - Sofia AD, to register the new shareholders in the Central Depository and to register the merger into the Registry agency.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Rositsa Doneva under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Elpharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on 12 September 2018 the Company bought 5 434 own shares representing 0.004% of the share capital of the Company, at a total value of 22 528.43 BGN on the Bulgarian Stock Exchange, the average price per share was 4.146 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 154 310, representing 6.79% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on 11 September 2018 the Company bought 28 own shares representing 0.00002% of the share capital of the Company, at a total value of 115.64 BGN on the Bulgarian Stock Exchange, the average price per share was 4.13 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 148 876, representing 6.79% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) draws attention to the fact that the registration for participation in the Extraordinary General meeting convened on 14 September 2018 will end at 10:45 am to comply with the opening hours announced for the start of the general meeting for the convenience of all shareholders.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on 10 September 2018 the Company bought 538 own shares representing 0.0004% of the share capital of the Company, at a total value of 2 221.94 BGN on the Bulgarian Stock Exchange, the average price per share was 4.13 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 148 848, representing 6.79% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for August 2018 the Company recorded an increase of sales revenues of 11% compared to the same month of 2017, including 7% decrease of domestic sales and an increase of 25% of export sales.

For the first eight months of this year, revenues from sales of products decreased by 4% compared to the same period of 2017, including 5% decrease of domestic sales and 3% decrease of export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

1. Financial report according to IFRS as at 30 June 2018

2. Notes to the financial report as at 30 June 2018

3. Management report as at 30 June 2018

4. Insider information as at 30 June 2018

5. Additional information as at 30 June 2018

6. Financial report according to BFCS standards as at 30 June 2018

7. Annex 9 as at 30 June 2018

8. Declaration as at 30 June 2018

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that, shareholders of Sopharma AD who have right to dividend, voted on the AGM held on June 15, 2018 and had accounts with the investment intermediary Beta Corp AD whose license has been suspended by the FSC with decision 675-II/09.07.2018, can receive their dividend at the cashier of the company in Sofia at 16, Iliensko Shose Str. every working day between 10-12 am and 2-4 pm.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that for July 2018 the Company recorded an increase of sales revenues of 10% compared to the same month of 2017, including an increase of 14% of export sales and a 3% increase of domestic sales.

For the first seven months of this year, revenues from sales of products decreased by 6% compared to the same period of 2017, including 5% decrease of domestic sales and 6% decrease of export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

1. Minutes of the Extraordinary General meeting of shareholders of Sopharma AD - 1 August 2018

2. Protocol to verify the quorum and the represented capital for participation in the EGM

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

1. Financial report according to IFRS as at 30 June 2018

2. Notes to the financial report as at 30 June 2018

3. Management report as at 30 June 2018

4. Insider information as at 30 June 2018

5. Additional information as at 30 June 2018

6. Financial report according to BFCS standards as at 30 June 2018

7. Annex 9 as at 30 June 2018

8. Declaration as at 30 June 2018

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD draws attention to the fact that the registration for participation in the Extraordinary General meeting convened on 1 August 2018 will end at 10:45 am to comply with the opening hours announced for the start of the general meeting for the convenience of all shareholders.

For registration and participation in IOSA, natural persons - shareholders must present an identity document. Legal entities - shareholders must provide an original or a certified copy of a current commercial / court registration certificate as well as a legal representative's identity document.

In view of the technical provision of the registration procedure for participation in the General meeting of shareholders, copies of the issued power of attorney should be submitted to the Company in hard copy or in electronic form at the latest by the end of the business day preceding the date of the General meeting, namely 17.00 on 31.07.2018.

Sopharma AD will receive and accept valid electronic notices and proxies by e-mail to the following e-mail address: ir@sopharma.bg according to the instructions described in the Invitation to convene the General Meeting.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that the Company will initiate dividend payment of the voted on the AGM held on June, 15 2018 dividend of 0.11 BGN on July, 23 2018.

The persons eligible for dividend are those present in the register of the Central Depository 14 days after the date of the AGM, i.e. June, 29 2018.

In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (the "Company") notifies that for June 2018 the Company recorded a decrease of sales revenues of 22% compared to the same month of 2017, including 2% decrease of domestic sales and a decrease of 34% of export sales.

For the first six months of this year, revenues from sales of products decreased by 8% compared to the same period of 2017, including 6% decrease of domestic sales and 10% decrease of export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on 29 June 2018 the Company bought 8 500 own shares representing 0.0063% of the share capital of the Company, at a total value of 34 825.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.097 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 148 310, representing 6.79% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

The Board of Directors, on the grounds of Art. 223 of the Commercial Law and Art. 115 of the Public Offering of Securities Act, convenes an Extraordinary General Meeting of Shareholders of Sopharma AD, which will be held on 01 August 2018 at 11.00 at the Company's registered office in Sofia, with place of holding: 5, Lachezar Stanchev Str., Sopharma Business Towers, building B, floor 3 and in the absence of a quorum on that date - on 15 August 2018 at the same place, with the same starting hour and the same agenda:

1. Taking a decision on the transformation by merger of Unipharm AD into Sopharma AD; Draft decision: GMS transforms Sopharma AD by merging Unipharm AD into it. As a result of the merger, the entire property of Unipharm AD will be transferred to Sopharma AD under the conditions of a joint succession.

2. Approval of a Transformation Agreement through merger of Unipharm AD into Sopharma AD, concluded on 17 May 2018 and of Additional Agreement No 1 of 13 June 2018; Draft decision: The GMS approves the Transformation Agreement through merger of Unipharm AD with Sopharma AD, concluded on 17 May 2018 and Additional Agreement No. 1 of 13 June 2018.

3. Approval of the Report of the Board of Directors of Sopharma AD to the shareholders of the Company regarding the merger of Unipharm AD into Sopharma AD; Draft decision: The GMS approves the Report of the Board of Directors of Sopharma AD to the shareholders of the Company regarding the merger of Unipharm AD into Sopharma AD.

4. Approval of the Auditor's Report under Art. 262m of the Commercial Law on the transformation by merger of Unipharm AD into Sopharma AD; Draft decision: The GMS approves the Auditor's Report under Art. 262m of the Commercial Law on the transformation by merger of Unipharm AD into Sopharma AD.

5. Approval of a Substantiated Report of the Board of Directors for transactions within the scope of Art. 114 of POSA; Draft decision: The GMS approves a Substantiated Report of the Board of Directors for Transactions within the scope of Article 114 of the POSA.

6. Empowerment within the meaning of Art.114, para 1 of the Public Offering of Securities Act, regarding the conclusion of a transaction, according to the Substantiated Report prepared by the Board of Directors; Draft decision: The GMS empowers the Board of Directors to conclude transactions for the inception of Sopharma AD as a co-debtor under the conditions of solidarity under an Investment Credit Agreement for the implementation of a project under an operational program and under a Contract for a credit line for working capital that is forthcoming to be concluded between DSK Bank EAD as a creditor and the subsidiary of Sopharma AD, Biopharm-Engineering AD, Sliven, as a borrower under the terms and conditions specified Substantiated Report prepared by the Board of Directors.

7. Election of a member of the Board of Directors of the Company; Draft decision: GMS elects Ivan Venetskov Badinsky for a member of the board of directors of Sopharma AD.

8. Miscellaneous

All shareholders of the company are invited to take part in the work of the General Meeting personally or through a representative.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on 28 June 2018 the Company bought 233 own shares representing 0.00017% of the share capital of the Company, at a total value of 959.96 BGN on the Bulgarian Stock Exchange, the average price per share was 4.12 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 139 810, representing 6.78% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on 27 June 2018 the Company bought 11857 own shares representing 0.0088% of the share capital of the Company, at a total value of 50 273.68 BGN on the Bulgarian Stock Exchange, the average price per share was 4.24 BGN.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on 26 June 2018 the Company bought 19 373 own shares representing 0.0144% of the share capital of the Company, at a total value of 82 568.31 BGN on the Bulgarian Stock Exchange, the average price per share was 4.26 BGN.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on 25 June 2018 the Company bought 28 951 own shares representing 0.021% of the share capital of the Company, at a total value of 123 372.40 BGN on the Bulgarian Stock Exchange, the average price per share was 4.26 BGN.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on 22 June 2018 the Company bought 4 740 own shares representing 0.0035% of the share capital of the Company, at a total value of 20 002.80 BGN on the Bulgarian Stock Exchange, the average price per share was 4.22 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 079 396, representing 6.74% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on 21 June 2018 the Company bought 4 250 own shares representing 0.0032% of the share capital of the Company, at a total value of 18 006.88 BGN on the Bulgarian Stock Exchange, the average price per share was 4.24 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 074 656, representing 6.73% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 .

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on 20 June 2018 the Company bought 2 200 own shares representing 0.00163% of the share capital of the Company, at a total value of 9 340.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.25 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 070 406, representing 6.73% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on 19 June 2018 the Company bought 106 own shares representing 0.0000786% of the share capital of the Company, at a total value of 450.50 BGN on the Bulgarian Stock Exchange, the average price per share was 4.25 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 068 206, representing 6.73% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

The Annual General Meeting of Shareholders of Sopharma AD was held on 15 June 2018, at 11.00 in Sofia, 5 Lachezar Stanchev Str., building B of commercial complex Sopharma Business Towers.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 .

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on 15 June 2018 the Company bought 2 272 own shares representing 0.0017% of the share capital of the Company, at a total value of 9 652.72 BGN on the Bulgarian Stock Exchange, the average price per share was 4.25 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 068 100, representing 6.73% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 - Secondary publication.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on 14 June 2018 the Company bought 1 000 own shares representing 0.00074% of the share capital of the Company, at a total value of 4 260.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.26 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 065 828, representing 6.73% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

W 2017 roku akcjonariusze spółki zdecydowali o wypłacie 0,10 BGN dywidendy na akcję. (PAP Biznes)

sar/ osz/

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies all shareholders of the Company about the decision of the AGM of Sopharma AD that took place on June 15, 2018 regarding the amount and type of dividend distributed and the terms and conditions for its distribution:

AGM approves the proposal by the Board of Directors for the distribution of dividend at the amount of 0.11 BGN /eleven stotinki/ per share with dividend right.

The persons eligible for dividend are those present in the register of the Central Depository 14 days after the day of the AGM on which the Annual Financial Report was approved and the decision for dividend was taken, namely June 29, 2018.

In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on 13 June 2018 the Company bought 24 062 own shares representing 0.0179% of the share capital of the Company, at a total value of 102 654.12 BGN on the Bulgarian Stock Exchange, the average price per share was 4.27 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 064 828, representing 6.72% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification by Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification by Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification by Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification by Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Ognian Donev - Executive director of Sopharma AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification from Donev Investments Holding AD under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification by Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification by Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 - Secondary publication.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that for May 2018 the Company recorded a decrease of sales revenues of 11% compared to the same month of 2017, including 1% increase of domestic sales and a decrease of 16% of export sales.

For the first five months of this year, revenues from sales of products decreased by 2% compared to the same period of 2017, including 1% increase of domestic sales and 3% decrease of export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD hereby informs that on 4 June 2018 the Company bought 6 600 own shares representing 0.00490% of the share capital of the Company, at a total value of 27900.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.23 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from 23 February 2018.

The total number of treasury shares after these transactions is 9 040 766, representing 6.707% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Notification by Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

With deep sorrow we announce that Mr. Andrey Breshkov, a member of the Board of Directors of Sopharma AD, unexpectedly passed away. May he rest in peace!

Until the Company elects a Member of the Board of Directors in accordance with the Commercial Law and the Public Offering of Securities Act, the Board will continue to perform its functions with four members.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

1.Financial report according to IFRS

2.Notes to the financial report

3.Management report

4.Insider information

5.Additional information

6.Financial report according to BFCS standards

7.Annex 9

8.Declaration

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: Sopharma AD notifies that due to the refusal issued by the Registry agency for the registration of the transformation through merger of Unipharm AD into Sopharma AD that started in September 2017, the Board of directors of Sopharma AD took a decision to close the previous and start a new procedure for transformation of Sopharma AD under the conditions of Chapter XVI of the Commercial Law and Art. 122 and et seq of the Public Offering of Securities Law, to be implemented through the merger of Unipharm AD, UIC 831537465, with headquarters and address of management in Sofia, Studentski district, Darvenitsa, 3 Trayko Stanoev Str. into Sopharma AD. The Board of Directors of the Company elects the investment intermediary Elana Trading AD, UIC 831470130, with headquarters and address of management in Sofia, 5, Lachezar Stanchev Str., as consultant in connection with the implementation of the transformation procedure.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (the "Company") notifies that for April 2018 the Company recorded an increase of sales revenues of 12% compared to the same month of 2017, including 1% increase of domestic sales and an increase of 21% of export sales.

For the first four months of this year, revenues from sales of products increased by 0,3% compared to the same period of 2017, including 0.5% increase of domestic sales and 0,1% increase of export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Walne Sopharmy zwołano na 15 czerwca.

W 2017 roku akcjonariusze spółki zdecydowali o wypłacie 0,10 BGN dywidendy na akcję.(PAP Biznes)

seb/

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

"The Board of Directors, on the grounds of Art. 223 of the Commercial Law and Art.115 of the Public Offering of Securities Act, convenes a General Meeting of Shareholders of Sopharma AD, which will be held on 15 June 2018 at 11.00 at the Company's registered office in Sofia, with place of holding: 5, Lachezar Stanchev Str., building B, and in the absence of a quorum on that date - on 29 June 2018 at the same place, with the same starting hour and the same agenda:

1. Approval of the annual report of the Board of Directors on the company's activities in 2017;

Draft decision: GMS approves the Annual Report of the Board of Directors on the company's activities in 2017.

2. Approval of the Report of the Investor Relations Director in 2017;

Draft decision: The GMS approves the Report of the Investor Relations Director in 2017.

3. Approval of the Audited Annual Individual Financial Statement of the Company for 2017;

Draft decision: The GMS approves the audited Annual Individual Financial Statement of the Company for 2017.

4. Approval of the Audited Annual Consolidated Financial Statement of the Company for 2017;

Draft decision: The GMS approves the audited Annual Consolidated Financial Statement of the Company for 2017;

5. Approval the Auditor's Report on the Audit of the Annual Individual Financial Statements of the Company for the year 2017;

Draft decision: The GMS approves the Auditor's Report on the Audit of the Annual Individual Financial Statements of the Company for the year 2017.

6. Approval the Auditor's Report on the Audit of the Annual Consolidated Financial Statements of the Company for the year 2017;

Draft decision: The GMS approves the Auditor's Report on the Audit of the Annual Consolidated Financial Statements of the Company for the year 2017.

7. Approval of a decision to distribute the Company's profit realized in 2017 and retained earnings from past periods;

Draft decision: GMS approves the proposal of the Board of Directors for the distribution of the company's profit in 2017 and undistributed profits from previous periods as follows: The total amount of the profit to be distributed amounts to BGN 43,010,955.52 (forty three million ten thousand nine hundred fifty-five leva and fifty-two stotinki) of which BGN 42,237,884.12 (forty two million two hundred thirty seven thousand eight hundred eighty four and twelve stotinki) profits realized in 2017 and BGN 773,071.40 (seven hundred seventy-three thousand seventy-one leva and forty cents) undistributed profits from past periods. After allocating 10% to a mandatory reserve, a dividend of BGN 0.11 per share is distributed. The amount left over after the allocation should be taken as an additional reserve of the company. The right to receive a dividend shall have the persons entered in the registers of the Central Depository as shareholders on the 14th day following the day of the General Meeting at which the Annual Financial Statement has approved a decision on the distribution of the profit was taken. The Company shall ensure the payment of the dividend voted to the shareholders at the General Meeting within 60 days of its execution. The costs of dividend payment are at the company's expense. The payment of the dividend is made with the assistance of the Central Depository. The shareholders with open accounts with an investment intermediary will receive their dividend through the respective intermediary and those shareholders who do not use the services of an investment intermediary will receive their dividends from the branches of Eurobank Bulgaria AD (Postbank) in the country.

8. Approval of the Audit Committee's report in 2017;

Draft decision: The GMS approves the Audit Committee's report on its activities in 2017.

9. Approval of a decision to discharge the members of the Board of Directors for their activity in 2017;

Draft decision: The GMS releases the members of the Board of Directors from responsibility for their activities in 2017.

10. Election of a registered auditor of the Company for 2018;

Draft decision: The GMS elects a registered auditor to verify and certify the Annual Financial Statements of the Company for 2018, as proposed by the Audit Committee, included in the items on the agenda.

11. Approval of the Report of the Board of Directors on the implementation of the Remuneration Policy of the members of the Board of Directors of the Company for 2017;

Draft decision: The General Meeting approves the Report of the Board of Directors on the Application of the Remuneration Policy of the Members of the Board of Directors of the Company for 2017.

12. Determination of the remuneration of the members of the Board of Directors for 2018;

Draft decision: Pursuant to Art. 24, para 3, letter A of the Articles of Association of the company, the GMS decided: the permanent remuneration of the members of the Board of Directors and the permanent remuneration of the Executive Director in 2018 remain unchanged.

13. Approval of a decision under Art. 24, para 3, letter B of the Articles of Association of the company;

Draft decision: Pursuant to Art. 24, para 3, letter B of the Articles of Association, the Executive Director of the company shall be paid an additional remuneration of 1% (one percent) of the amount of profits realized in 2017 according to the approved Annual Financial report.

14. Approval of a decision to determine a percentage of the profit realized in 2017 to be distributed among the members of the senior management team of the company, subject to the requirements of Art. 26a, item 12 of the Articles of Association of the company;

Draft decision: The General Meeting adopts a decision of 2% (two percent) of the profit realized in 2017 to be distributed among the members of the company's senior management team, subject to the requirements of Art. 26a, item 12 of the Articles of Association of the Company.

15. Approval of a Substantiated Report of the Board of Directors for transactions within the scope of Art. 114, para 1 of POSA;

Draft decision: GMS adopts the Substantiated Report of the Board of Directors for transactions within the scope of Art. 114, para 1 of POSA.

16. Empowerment within the meaning of Art. 114, para 1 of POSA regarding a transaction between Sopharma AD and Telecomplect AD;

Draft decision: GMS empowers the representative of the public company Sopharma AD to conclude on behalf of the company as a contracting entity a transaction with Telecomplect AD as a contractor falling within the scope of Art. 114, para 1, in conjunction with paragraph 6 of the same provision of POSA, under the conditions specified in the Substantiated Report.

17. Empowerment within the meaning of Art. 114, para 1 of POSA regarding a transaction between Sopharma AD and Sopharma Trading AD;

Draft decision: GMS empowers the representative of the public company Sopharma AD as a seller to conclude a transaction with Sopharma Trading AD as a buyer falling within the scope of Art. 114, para 1 of the POSA, under the conditions specified in the Substantiated Report.

18. Empowerment within the meaning of Art.114, para 1 of POSA concerning the assumption of a commitment as a co-debtor by Sopharma AD under an overdraft loan agreement between Eurobank Bulgaria AD as creditor and Momina krepost AD as a debtor.

Draft decision: The GMS empowers the representative of the public company Sopharma AD to conclude on behalf of the company as a co-debtor an overdraft loan agreement with creditor Eurobank Bulgaria AD and Momina Krepost AD as a debtor - a transaction falling within the scope of Art. 114, para 1 of POSA, according to the conditions stated in the Substantiated Report.

19. Empowerment within the meaning of Art.114, para 1 of POSA regarding a transaction between Sopharma AD and Sopharma Properties REIT;

Draft decision: The GMS empowers the representative of the public company Sopharma AD to conclude a transaction with Sopharma Properties REIT - a transaction falling within the scope of Art. 114, para 1 of POSA, according to the conditions stated in the Substantiated Report.

20. Approval of a decision for granting of shares in the capital of the company as a bonus for 2018 for the persons working in Sopharma AD on a labor contract or a management contract;

Draft decision: The GMS decided shares of the Company to be granted as a bonus for 2018 on the occasion of the 85th anniversary of the Company to all persons having an employment relationship with the Company or working under a management contract at the date of this decision taking the bonus is at the expense of the Company's own shares. The proposal of the Board of Directors included in the agenda items contains detailed information on how to determine the number of shares to be given to each person. The GMS empowers the Chairman of the Board of Directors and Executive Director to perform all necessary actions for the final transfer from the Company of the shares provided as a bonus to the employees.

21. Miscellaneous

All shareholders of the company are invited to take part in the work of the General Meeting personally or through a representative.

Written materials for the GMS are available to shareholders at the headquarters of the Company in Sofia, 16 Iliensko shose Str., the Records Department, every workday from 8:30 AM to 5:00 PM. The invitation, together with the written materials related to the items of the agenda of the Meeting, have been sent to the Financial Supervision Commission, are disclosed to the public and are published on the website of Sopharma AD - www.sopharmagroup.com from the moment the invitation is announced in the Commercial Register until the completion of the GMS.

Pursuant to Art. 115b, para 1 of POSA the right to vote in the General Meeting is exercised by the persons registered as such with the right to vote in the registers of the Central Depository 14 days before the date of the General Meeting, the respective valid date for the current Regular General Meeting of Shareholders, is 1 June 2018. Persons registered as such with voting rights at that date are entitled to participate and exercise their voting rights at the General Meeting. To determine the circle of voting persons at the General Meeting, scheduled for 15 June 2018, the company will obtain a Book of Shareholders from the Central Depository AD valid as at 1 June 2018.

According to the provision of Art. 187a, para 3 of the Commercial Law, the exercise of all rights, including the right to vote, on the treasury shares bought back by the company shall cease until the moment of their transfer.

On the grounds of Art. 118, para 2, item 4 of POSA, persons holding together or separately at least 5 per cent of the capital of the public company Sopharma AD may request the inclusion of agenda items and propose resolutions on already included agenda items for the General Meeting under the provisions of Art. 223a of the Commercial Law. Not later than 15 days before the opening of the General Meeting, these shareholders shall submit for announcement with the Commercial Register a list of the items that will be included in the agenda and the respective proposals for decisions on them, respectively proposals for decisions on items already on the agenda. With the announcement in the Commercial Register, the items are considered included in the proposed agenda of the General Meeting, respectively proposals for decisions on items already on the agenda. At the latest on the next business day, following the announcement, the shareholders shall submit the list of items, the proposals for decisions and the written materials at the address of the company's management, as well as to the Financial Supervision Commission and the regulated market in which the shares of the company are admitted to trading.

Shareholders have the right, subject to the requirements of the law, to make substantive proposals for decisions on any item included on the agenda until the debate on this item, is terminated and before the General Meeting votes a resolution on the respective item. In exercising this right, the restriction provided in Art. 118, para 3 of the Public Offering of Securities Act is valid.

During the General Meeting, the shareholders of the company have the right to ask questions on all items of the agenda, as well as questions about the economic and financial situation and the commercial activity of the company, whether these are related to the agenda or not.

The registration of the shareholders for participation in the General Meeting will take place on the announced day of its holding from 9:30 to 11:00 AM.

For registration and participation in the GMS, the natural persons - shareholders present an identity document. Legal entities - shareholders shall present an original or a certified copy of a current commercial / judicial registration certificate as well as an identity document of the legal representative.

Rules for proxy voting: Pursuant to the provisions of Art. 18, para 2 of the Articles of Association of the Company a proxy of shareholders in the General Meeting must contain an explicit written letter of attorney for the particular General Meeting with a minimum content as per Art.116, para 1 of POSA.

In case a shareholder - legal entity is represented by a physical person, the authorized person must provide their identity document, original or a certified copy, of a current certificate of commercial/court registration of the shareholder - legal entity, as well as an explicit written letter of attorney for the particular General Meeting with content as per Art. 116, para 1 of POSA, signed by the legal representative of the shareholder - legal entity, entered in the current certificate of commercial/court registration.

In case a shareholder is represented by a legal entity, the person, representing the proxy, apart from their identification document, must present an original or a certified copy of a current certificate of commercial/court registration of the proxy - legal entity, an explicit written letter of attorney for the particular General Meeting with content as per Art. 116, para 1 of POSA, issued by the shareholder. If the shareholder is a legal person, the person representing the proxy must also present an original or a certified copy of a current certificate of commercial/court registration of the shareholder.

The power of attorney should contain:

• A statement on the rights of the proxy in the cases of further included issues and / or proposals for decisions under Art. 118, para 2, item 4 of the Public Offering of Securities Act in connection with Art. 223a of the Commercial Law;

• A statement on the rights of the proxy in the hypothesis of Art. 231, para 1 of the Commercial Law;

• A statement on the right of the proxy to make substantive proposals for decisions on the items included in the agenda until the discussion on the respective issue - Art.115, para 3 of the Public Offering of Securities Act. In this case, the authorizing officer should explicitly indicate in the power of attorney a way to vote or give the proxy the right to vote at his own discretion.

Pursuant to Art. 116, para 4 of POSA the re-authorization with the rights granted to the proxy according to the power of attorney given to him, as well as the power of attorney given in violation and / or in inconsistency with the provisions of Art. 116, para 1 of the POSA is void.

A commercial / court registration certificate as well as a power of attorney for representation in the General Meeting issued in a foreign language must be accompanied by a translation into Bulgarian, certified in accordance with Art. 2a, para 2 of the Regulations on legalizations, certification and translation of documents and other papers. The translation of official documents is done by an interpreter engaged at a company that has signed a contract with the Ministry of Foreign Affairs. The fact that the translator is registered with such a company is certified by the Ministry of Foreign Affairs with the signature of the translator or with an explicit certificate together with a statement by the translator that he has not been removed from the list at the Ministry of Foreign Affairs. If there is a discrepancy between the texts, the data in the Bulgarian translation will be accepted as valid.

The Board of directors of Sopharma AD shall provide a sample paper power of attorney together with the materials for the General meeting. The power of attorney form is also available on the company's website at www.sopharmagroup.com.

In view of the technical support of the registration procedure for participation in the General Meeting of Shareholders, copies of the power of attorney should be submitted to the company on paper or in electronic form at the latest by the end of the working day preceding the date of the General Meeting; namely 17:00 14 June 2018.

Sopharma AD will receive and accept valid electronic notifications and proxies by e-mail to the following e-mail: ir@sopharma.bg the electronic messages should be signed with an universal electronic signature (UES) by the legal representative or natural person and accompanied by an electronic document (electronic sample) of the power of attorney, which is also signed with an universal electronic signature (UES) by the legal representative.

Pursuant to Art. 16a, para 3 of the Articles of Association of the Company, the Board of directors informs shareholders that at the General Meeting scheduled for 15 June 2018, and in the absence of a quorum on that date - for 29 June 2018, voting by correspondence and electronic means will be accepted, observing following rules:

1. Pursuant to Art. 16a of the Articles of Association, shareholders may exercise their voting rights before the date of the meeting by correspondence.

2. The voting right at the General Meeting of Shareholders of Sopharma AD, exercised through correspondence, is an explicit, written, notarized statement of will, issued by a shareholder of the company, which is for the particular meeting of the General Meeting of Shareholders and contains data on: identification of the shareholder in accordance with the requirements for registration for participation in the General Meeting of Shareholders; the number of shares the shareholder owns; the agenda of the items proposed for discussion at the particular meeting of the General Meeting of Shareholders of the Company, according to the Invitation to the General Meeting announced in the Commercial Register; proposals for decisions on each of the items on the agenda; the way of voting on each of the items on the agenda (for each of the items on the agenda only one of the following voting methods should be mentioned: "For", "Against" or "Abstain"); date and signature.

3. The necessary data for identifying a shareholder - natural person is: the full names, a single civilian number (EGN) and an address. The necessary data for identification of a shareholder - legal entity is: name, registered office and address of management, unified identification code (UIC) and the full name of the representative of the company.

4. The declaration referred to in para 2 above, made in a foreign language, shall be accompanied by a translation into Bulgarian language, certified in accordance with Art. 2a, para 2 of the Regulations on legalization, certification and translation of documents and other papers. The translation of official documents is done by an interpreter engaged at a company that has signed a contract with the Ministry of Foreign Affairs. The fact that the translator is registered with such a company is certified by the Ministry of Foreign Affairs with the signature of the translator or with an explicit certificate together with a statement by the translator that he has not been removed from the list at the Ministry of Foreign Affairs. If there is a discrepancy between the texts, the data in the Bulgarian translation will be accepted.

5. In case the voting right is exercised through correspondence by a shareholder - legal person, the explicit statement must be accompanied by an original or a certified copy of a current certificate of commercial registration of the respective shareholder company. A certificate of commercial registration issued in a foreign language must be accompanied by a translation into Bulgarian, subject to the conditions set forth in para 4 above.

6. As a valid means of exercising voting rights through correspondence, the shareholders of Sopharma AD may use any of the following exhaustively listed methods: mail - by letter sent to the company with a return receipt, certifying the moment of receiving the letter from the company; e-mail - via an electronic message that must be signed with an universal electronic signature (UES) by the shareholder and accompanied by an electronic document (electronic sample) of the statement, which is also signed with an universal electronic signature (UES) by the shareholder; courier - by letter sent to the company by a courier service chosen by the shareholder.

7. Sopharma AD shall accept the validity of the vote by correspondence only if the written statement with the vote of the respective shareholder, irrespective of the preferred method of sending, was received by the company not later than 14 June 2018, which is the last business day, prior to the date set for the General Meeting of Shareholders.

8. In case a shareholder of Sopharma AD, who exercised his / her voting right through correspondence, attends the General Meeting personally on 15 June 2018, the voting rights exercised by him by correspondence shall be valid unless the shareholder states differently upon registration for participation in the meeting. In such cases, in items on which the shareholder votes in person at the General Meeting, the voting rights he has exercised through correspondence will not be honored.

9. Address for correspondence by mail or courier: Sofia, 1756, 5 Lachezar Stanchev Str., Sopharma Business Towers, Building A, fl. 11 for Sopharma AD - to the attention of the Investor Relations Director.

Address for correspondence via e-mail: ir@sopharma.bg

Pursuant to Art. 227, para 3 of the Commercial Law, in the absence of a quorum of the date of the General Meeting of Shareholders announced by this invitation, the same shall be held on 29 June 2018 at 11:00 AM on the same place and on the same agenda. In this case, items on the agenda may not be included under the order of Art. 223a of the Commercial Law."

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on April 30, 2018, the Registry Agency issued a refusal ą 20180411164207 of the declared transformation of Unipharm AD into Sopharma AD under the Transformation Agreement of September, 14 2017 and the Additional Agreement of November, 8 2017.

The companies are considering to launch a new transformation procedure as soon as possible.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Audited Financial Report according to IFRS

Notes to the financial report

Management report

Financial Report according to BFCS standards

Auditor's report

Corporate Governance Declaration

Declaration by responsible directors

Non-financial Declaration to the Annual Financial Statements

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

1. Financial report according to IFRS as at 31 March 2018

2. Notes to the financial report as at 31 March 2018

3. Management report as at 31 March 2018

4. Insider information as at 31 March 2018

5. Additional information as at 31 March 2018

6. Financial report according to BFCS standards as at 31 March 2018

7. Annex 9 as at 31 March 2018

8. Declaration as at 31 March 2018

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that the filed on March 29, 2018 in the Commercial Register invitation for convening the Regular General Meeting of Shareholders of Sopharma AD on 11 May was not announced in accordance with the requirement of Art. 223, para 5 of the Commercial Law and the GMS cannot be conducted on this date.

The Board of Directors will propose another date for the GMS and will take the appropriate actions to convene it in the shortest possible time.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sofia, Bulgaria, April 5, 2018 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for March 2018 the Company recorded a decrease of sales revenues of 10% compared to the same month of 2017, including 1% increase of domestic sales and a decrease of 19% of export sales.

For the first three months of this year, revenues from sales of products decreased by 3% compared to the same period of 2017, including 0.5% increase of domestic sales and 6% decrease of export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Audited Financial Report according to IFRS

Notes to the financial report

Management report

Financial Report according to BFCS standards

Auditor's report

Corporate Governance Declaration

Report regarding the application of the remuneration policy

Declaration by responsible directors

Non-financial Declaration to the Annual Financial Statement

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sofia, Bulgaria, March 6, 2018 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for February 2018 the Company recorded an increase of sales revenues of 2% compared to the same month of 2017, including 8% increase of domestic sales and same level of export sales.

For the first two months of this year, revenues from sales increased by 1% compared to the same period of 2017, including 2% increase of export sales and same level of domestic sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

1. Financial Statements

2. Notes to the Financial Statements

3. Management report

4. Templates of the financial reports approved by the Bulgarian FSC

5. Declaration of the responsible directors

6. Annex 9

7. Additional information

8. List of insider information under Art. 7 of Regulation (EU) 596/2014

9. Financial results for 2017

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

MINUTES OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 23 February 2018

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on 23.02.2018 an Extraordinary general meeting of shareholders took place.

The General meeting of shareholders approved the decision for transformation of Sopharma AD, UIC: 831902088 by merging Unipharm AD, UIC: 831537465 into it. As a result of the merger, the entire property of Unipharm AD, UIC: 831537465 will be transferred to Sopharma AD, UIC: 831902088 under the conditions of general succession.

The General meeting of shareholders approved the Contract for transformation through merger of Unipharm AD into Sopharma AD, concluded on 14.09.2017, Additional Agreement No. 1 of 08.11.2017 to it (the "Contract for transformation through merger ").

The General meeting of shareholders approved the Report of the Board of Directors of Sopharma AD to the shareholders of the company regarding the transformation through merger of Unipharm AD into Sopharma AD.

The General meeting of shareholders approved the Auditor's Report under Art. 262m of the CA on the transformation through merger of Unipharm AD into Sopharma AD.

The General meeting of shareholders approved changes in the Company's Articles of Association which allows the payment of an interim dividend on the basis of a 6-month financial statement under the Public Offering of Securities Act.

The General Meeting of Shareholders, on the grounds of Art.187b of the Commercial Law and Art.111, para 5 of POSA, approved a resolution for the acquisition of own shares from the capital of the Company under the following conditions: up to 10% of the total number of shares issued by the company, but not more than 3% in each calendar year; term of the acquisition - no longer than 5 (five) years; minimum price for acquisition - not less than the nominal value per share of the company's capital; maximum price for acquisition - BGN 5.50 per share;

The minutes of the General Meeting of Shareholders of Sopharma AD, held on 23.02.2018, will be sent to you within the statutory term. All conversion documents are available as part of the materials of the extraordinary general meeting.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sofia, Bulgaria, February 8, 2018 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on 29 December 2017 the Company bought 1186 own shares representing 0.00088% of the share capital of the Company, at a total value of 5080.82 BGN on the Bulgarian Stock Exchange, the average price per share was 4.28 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 8 904 000, representing 6.61% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sofia, Bulgaria, February 5, 2018 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for January 2018 the Company recorded an increase of sales revenues of 3% compared to the same month of 2017, including 5% increase of export sales and same level of domestic sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sofia, Bulgaria, January 30, 2018 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) received a notification for the sale of 250 000 shares, representing 0.19% of its capital, by CUPF Allianz Bulgaria. After the transaction the share of CUPF Allianz Bulgaria in the capital of Sopharma AD reached 4.99%.

The date of the registration of the transaction with the Central Depository is 24 January 2018.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

PRELIMINARY INDIVIDUAL FINANCIAL STATEMENTS FOR 2017

1. Financial Statements

2. Notes to the Financial Statements

3. Management report

4. Templates of the financial reports approved by the Bulgarian FSC

5. Declaration of the responsible directors

6. Insiders' information

7. Additional information

8. List of insider information under Art. 7 of Regulation (EU) 596/2014

9. Results for 2017

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

1. Taking a decision for transformation through merger of Unipharm AD into Sopharma AD.

Draft decision: GMS transforms Sopharma AD by merging Unipharm AD into it. As a result of the merger, the entire property of Unipharm AD will be transferred to Sopharma AD under the conditions of general succession.

2. Approval of the Contract for transformation through merger of Unipharm AD into Sopharma AD, concluded on 14.09.2017 and of Additional Agreement No1 of 08.11.2017 to it.

Draft decision: The GMS approves the Contract for transformation through merger of Unipharm AD into Sopharma AD, concluded on 14.09.2017, Additional Agreement No. 1 of 08.11.2017 to it (the "Contract for transformation through merger ").

3. Approval of the Report of the Board of Directors of Sopharma AD to the shareholders of the company regarding the transformation through merger of Unipharm AD into Sopharma AD.

Draft decision: The GMS approves the Report of the Board of Directors of Sopharma AD to the shareholders of the company regarding the transformation through merger of Unipharm AD into Sopharma AD.

4. Approval of the Auditor's Report under Art. 262m of the CA on the transformation through merger of Unipharm AD into Sopharma AD.

Draft decision: The GMS approves the Auditor's Report under Art. 262m of the CA on the transformation through merger of Unipharm AD into Sopharma AD.

5. Approval of changes in the Company's Articles of Association.

Draft decision: The GMS approves changes in the Company's Articles of Association according to a proposal of the Board of Directors, included in the materials for the EGMS.

6. Taking a decision for acquisition of own shares.

Draft decision: The General Meeting of Shareholders, on the grounds of Art.187b of the Commercial Law and Art.111, para 5 of POSA, approves a resolution for the acquisition of own shares from the capital of the Company under the following conditions: up to 10% of the total number of shares issued by the company, but not more than 3% in each calendar year; term of the acquisition

- no longer than 5 (five) years; minimum price for acquisition - not less than the nominal value per share of the company's capital; maximum price for acquisition - BGN 5.50 per share; The General Meeting empowers the Board of Directors of the company to determine all other parameters of the acquisition and to carry out the necessary factual and legal actions for the implementation of the decision of the General Meeting of Shareholders.

7. Miscellaneous.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Skup miałby trwać do pięciu lat. Minimalna cena nabycia to nie mniej niż nominalna wartość jednej akcji, a maksymalna cena nabycia to 5,50 nowego lewa bułgarskiego. Według średniego kursu NBP z wtorku oznacza to kwotę 11,72 zł za akcję. (PAP Biznes)

sar/ ana/

Podstawa prawna: art. 17. 1 MAR.

1. Taking a decision for transformation through merger of Unipharm AD into Sopharma AD.

Draft decision: GMS transforms Sopharma AD by merging Unipharm AD into it. As a result of the merger, the entire property of Unipharm AD will be transferred to Sopharma AD under the conditions of general succession.

2. Approval of the Contract for transformation through merger of Unipharm AD into Sopharma AD, concluded on 14.09.2017 and of Additional Agreement No1 of 08.11.2017 to it.

Draft decision: The GMS approves the Contract for transformation through merger of Unipharm AD into Sopharma AD, concluded on 14.09.2017, Additional Agreement No. 1 of 08.11.2017 to it (the "Contract for transformation through merger ").

3. Approval of the Report of the Board of Directors of Sopharma AD to the shareholders of the company regarding the transformation through merger of Unipharm AD into Sopharma AD.

Draft decision: The GMS approves the Report of the Board of Directors of Sopharma AD to the shareholders of the company regarding the transformation through merger of Unipharm AD into Sopharma AD.

4. Approval of the Auditor's Report under Art. 262m of the CA on the transformation through merger of Unipharm AD into Sopharma AD.

Draft decision: The GMS approves the Auditor's Report under Art. 262m of the CA on the transformation through merger of Unipharm AD into Sopharma AD.

5. Approval of changes in the Company's Articles of Association.

Draft decision: The GMS approves changes in the Company's Articles of Association according to a proposal of the Board of Directors, included in the materials for the EGMS.

6. Taking a decision for acquisition of own shares.

Draft decision: The General Meeting of Shareholders, on the grounds of Art.187b of the Commercial Law and Art.111, para 5 of POSA, approves a resolution for the acquisition of own shares from the capital of the Company under the following conditions: up to 10% of the total number of shares issued by the company, but not more than 3% in each calendar year; term of the acquisition

- no longer than 5 (five) years; minimum price for acquisition - not less than the nominal value per share of the company's capital; maximum price for acquisition - BGN 5.50 per share; The General Meeting empowers the Board of Directors of the company to determine all other parameters of the acquisition and to carry out the necessary factual and legal actions for the implementation of the decision of the General Meeting of Shareholders.

7. Miscellaneous.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD notifies that for December 2017 the Company recorded an increase of sales revenues of 21% compared to the same month of 2016, including 73% increase of domestic sales and 4% increase of export sales.

For 2017, revenues from sales increased by 13% compared to 2016, including 3% increase of domestic sales and a 20% increase of export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date of the transaction Operation Number of shares Unit price (BGN)

29.12.2017 Buy 1 354 4.2800

29.12.2017 Buy 705 4.2810

29.12.2017 Buy 1 568 4.2830

29.12.2017 Buy 873 4.2830

29.12.2017 Buy 500 4.2830

29.12.2017 Buy 427 4.2830

29.12.2017 Buy 473 4.2830

29.12.2017 Buy 1 073 4.2830

29.12.2017 Buy 27 4.2830

29.12.2017 Buy 500 4.2830

29.12.2017 Buy 81 4.2830

29.12.2017 Buy 269 4.2830

29.12.2017 Buy 1 619 4.2830

29.12.2017 Buy 31 4.2830

29.12.2017 Buy 181 4.2830

29.12.2017 Buy 1 319 4.2830

29.12.2017 Buy 400 4.2830

29.12.2017 Buy 81 4.2830

29.12.2017 Buy 1 519 4.2830

29.12.2017 Buy 719 4.2830

29.12.2017 Buy 281 4.2830

29.12.2017 Buy 672 4.2830

29.12.2017 Buy 328 4.2840

29.12.2017 Buy 200 4.2750

29.12.2017 Buy 300 4.2750

29.12.2017 Buy 500 4.2750

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:

Date of the transaction Operation Number of shares Unit price (BGN)

29.12.2017 Buy 200 4.2750

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date of the transaction Operation Number of shares Unit price (BGN)

21.12.2017 Buy 1 609 4.2700

21.12.2017 Buy 3 391 4.2700

21.12.2017 Buy 121 4.2700

21.12.2017 Buy 199 4.2700

21.12.2017 Buy 1 000 4.2700

21.12.2017 Buy 500 4.2700

21.12.2017 Buy 130 4.2700

22.12.2017 Buy 1 628 4.2700

22.12.2017 Buy 372 4.2700

22.12.2017 Buy 950 4.2830

22.12.2017 Buy 100 4.2830

22.12.2017 Buy 1 490 4.2830

22.12.2017 Buy 510 4.2830

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on 20 December 2018 Sopharma AD received an approval from the FSC of the contract for transformation through merger of Unipharm AD in Sopharma AD and reports of the boards of directors and the independent evaluators. The fair price of the participants in the transformation is based on widely accepted evaluation methods. Based on the fair price the participants in the transformation reached a ratio of exchange of 0. 891512, meaning that one share of Unipharm AD will be exchanged for 0. 891512 shares of Sopharma AD from the treasury shares available to the receiving company.

The terms and conditions of the merger are available in detail in the Contract for transformation through merger and the reports of the boards of directors and the independent evaluators which are subject to approval by the general meetings of shareholders of both companies. The procedures for convening general meetings for both companies will be initiated in the beginning of 2018.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:

Date of the transaction Operation Number of shares Unit price (BGN)

20.12.2017 Buy 5 000 4.2700

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date of the transaction Operation Number of shares Unit price (BGN)

20.12.2017 Buy 543 4.2700

20.12.2017 Buy 3 000 4.2700

20.12.2017 Buy 3 000 4.2700

20.12.2017 Buy 1 457 4.2700

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD hereby informs that on 20 December 2017 the Company bought 10 934 own shares representing 0.0081% of the share capital of the Company, at a total value of 46 697.52 BGN on the Bulgarian Stock Exchange, the average price per share was 4.27 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 9 032 980, representing 6.70 % of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date of the transaction Operation Number of shares Unit price (BGN)

19.12.2017 Buy 300 4.2820

19.12.2017 Buy 108 4.2800

19.12.2017 Buy 400 4.2800

19.12.2017 Buy 192 4.2800

19.12.2017 Buy 22 4.2750

19.12.2017 Buy 450 4.2750

19.12.2017 Buy 28 4.2750

19.12.2017 Buy 500 4.2710

19.12.2017 Buy 1 000 4.2700

19.12.2017 Buy 1 000 4.2700

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:

Date of the transaction Operation Number of shares Unit price (BGN)

18.12.2017 Buy 200 4.2850

18.12.2017 Buy 45 4.2900

18.12.2017 Buy 15 4.2900

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date of the transaction Operation Number of shares Unit price (BGN)

18.12.2017 Buy 1 455 4.2900

18.12.2017 Buy 45 4.2900

18.12.2017 Buy 500 4.2900

18.12.2017 Buy 500 4.2900

18.12.2017 Buy 1 800 4.2850

18.12.2017 Buy 200 4.2820

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:

Date and time of the transaction Operation Number of shares Unit price (BGN)

14.12.2017 Buy 600 4.285

15.12.2017 Buy 335 4.290

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date of the transaction Operation Number of shares Unit price (BGN)

15.12.2017 Buy 76 4.2880

15.12.2017 Buy 500 4.2900

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD hereby informs that on 15 December 2017 the Company bought 130 166 own shares representing 0.0966% of the share capital of the Company, at a total value of 558 151.81 BGN on the Bulgarian Stock Exchange, the average price per share was 4.2880 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 9 022 046, representing 6.693 % of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date of the transaction Operation Number of shares Unit price (BGN)

14.12.2017 Buy 4 000 4.2850

14.12.2017 Buy 224 4.2850

14.12.2017 Buy 500 4.2800

14.12.2017 Buy 100 4.2890

14.12.2017 Buy 100 4.2810

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD hereby informs that on 14 December 2017 the Company bought 3 000 own shares representing 0.0022% of the share capital of the Company, at a total value of 12 855.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.285 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 8 891 880, representing 6.60 % of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date of the transaction Operation Number of shares Unit price (BGN)

13.12.2017 Buy 165 4.2960

13.12.2017 Buy 5 000 4.2800

13.12.2017 Buy 835 4.2800

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD hereby informs that on 13 December 2017 the Company bought 6 251 own shares representing 0.0046% of the share capital of the Company, at a total value of 26 753.18 BGN on the Bulgarian Stock Exchange, the average price per share was 4.28 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 8 888 880, representing 6.59 % of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:

Date and time of the transaction Operation Number of shares Unit price (BGN)

05.12.2017 Buy 3000 4.27

06.12.2017 Buy 4000 4.27

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date of the transaction Operation Number of shares Unit price (BGN)

08.12.2017 Buy 2 000 4.2700

11.12.2017 Buy 3 000 4.2700

11.12.2017 Buy 2 000 4.2700

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:

Date and time of the transaction Operation Number of shares Unit price (BGN)

05.12.2017 Buy 3000 4.27

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:

Date and time of the transaction Operation Number of shares Unit price (BGN)

05.12.2017 Buy 2 000 4.2700

06.12.2017 Buy 1 000 4.2700

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:

Date of the transaction Operation Number of shares Unit price (BGN)

05.12.2017 Buy 7 000 4.2700

05.12.2017 Buy 6 500 4.2700

05.12.2017 Buy 6 500 4.2700

06.12.2017 Buy 600 4.2700

07.12.2017 Buy 200 4.2700

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date of the transaction Operation Number of shares Unit price (BGN)

05.12.2017 Buy 6000 4.27

05.12.2017 Buy 2000 4.27

06.12.2017 Buy 400 000 4.27

06.12.2017 Buy 6 000 4.27

06.12.2017 Buy 6 000 4.27

06.12.2017 Buy 2 000 4.27

06.12.2017 Buy 3 000 4.27

06.12.2017 Buy 567 4.27

07.12.2017 Buy 2000 4.27

07.12.2017 Buy 1000 4.27

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on 8 December 2017 the Company received two notifications from Rompharm Company OOD for the sale of shares from the capital of Sopharma AD.

The first notification concerns the sale of 6 000 000 shares, as a result of which the share of Rompharm Company OOD in the capital of Sopharma AD fell under 15% to 12.88%. The date of the registration of the transaction with the Central Depository is 7 December 2017.

The first notification concerns the sale of 4 685 000 shares, as a result of which the share of Rompharm Company OOD in the capital of Sopharma AD fell under 10% to 9.41%. The date of the registration of the transaction with the Central Depository is 8 December 2017.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that on 8 December 2017 the Company received two notifications from Rompharm Company OOD for the sale of shares from the capital of Sopharma AD.

The first notification concerns the sale of 5 000 000 shares, as a result of which the share of Rompharm Company OOD in the capital of Sopharma AD fell under 15% to 12.88%. The date of the registration of the transaction with the Central Depository is 7 December 2017.

The first notification concerns the sale of 4 685 000 shares, as a result of which the share of Rompharm Company OOD in the capital of Sopharma AD fell under 10% to 9.41%. The date of the registration of the transaction with the Central Depository is 8 December 2017.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD hereby informs that on 7 December 2017 the Company bought 105 844 own shares representing 0.0785% of the share capital of the Company, at a total value of 451 979.92 BGN on the Bulgarian Stock Exchange, the average price per share was 4.27 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 8 882 629, representing 6.590% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD hereby informs that on 6 December 2017 the Company bought 2 691 292 own shares representing 1.997% of the share capital of the Company, at a total value of 11 491 816.84 BGN on the Bulgarian Stock Exchange, the average price per share was 4.27 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 8 776 785, representing 6.511% of the share capital of the Company. With these transactions Sopharma AD passes the 5% threshold for treasury shares.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD hereby informs that on 6 December 2017 the Company bought 3 061 292 own shares representing 2.271% of the share capital of the Company, at a total value of 13 071 716.84 BGN on the Bulgarian Stock Exchange, the average price per share was 4.27 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 9 146 785, representing 6.786% of the share capital of the Company. With these transactions Sopharma AD passed the threshold of 5% for the treasury shares.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

SOPHARMA AD hereby informs that from 1st to 5th December 2017 the Company bought 924 732 own shares representing 0.686% of the share capital of the Company, at a total value of 3 948 605.64 BGN on the Bulgarian Stock Exchange, the average price per share was 4.27 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 6 085 493, representing 4.51% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Sopharma AD notifies that for November 2017 the Company recorded an increase of sales revenues of 11% compared to the same month of 2016, including 11% increase of domestic sales and 12% increase of export sales.

For the first eleven months of this year, revenues from sales increased by 12% compared to the same period of 2016, including 1% decrease of domestic sales and a 21% increase of export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

CONSILIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 SEPTEMBER 2017

1. Financial Statements

2. Notes to the Financial Statements

3. Management report

4. Templates of the financial reports approved by the Bulgarian FSC

5. Declaration of the responsible directors

6. Annex 9

7. Additional information

8. List of insider information under Art. 7 of Regulation (EU) 596/2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

We would like to notify that within the fourteenth meeting of the Vienna Economic Forum "Vienna future dialogue 2017" Ognian Donev PhD, Chairman of the Board of Directors and Executive Director of Sopharma AD received the Forum award for "Contribution to the economic development on national and regional level".

In 2015 Mr. Donev was elected vice-president of the Vienna Economic Forum and on the November meeting this year he was invited to moderate the panel "Digital economy - expectations and reality". Each year the Forum gathers guests from different areas - politicians, economists, business leaders etc.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

We would like to notify that within the fourteenth meeting of the Vienna Economic Forum "Vienna future dialogue 2017" Ognian Donev PhD, Chairman of the Board of Directors and Executive Director of Sopharma AD received the Forum award for "Contribution to the economic development on national and regional level".

In 2015 Mr. Donev was elected vice-president of the Vienna Economic Forum and on the November meeting this year he was invited to moderate the panel "Digital economy - expectations and reality". Each year the Forum gathers guests from different areas - politicians, economists, business leaders etc.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

We would like to notify that an Annual meeting with the investors of Sopharma AD was held on 3 November 2017, which started at 2.30 pm and ended at 6.30 pm. The following announcement regarding the liability was made:

"Please note that at the Annual Meeting with the Investors of SOPHARMA AD (" the Company ") can be made oral and written "forward looking statements" about future events, which are essentially uncertain because they do not concern only past or current facts. All such statements are also based on a number of assumptions, expectations, forecasts and preliminary data for future events, determined by factors beyond the control of SOPHARMA AD, which are therefore uncertain and should not be considered as a reliable indicator of future results. The Company undertakes no obligation to publicly update or revise any forward-looking statements whether as a result of new information, future events, or otherwise, except as may be required by applicable law. The information and opinions set forth in this meeting are current as of the date of the meeting and are subject to change without prior notice. Neither the information disclosed at this meeting, nor any part of it, nor the fact of its distribution, may serve as a ground upon which a party may invoke or in relation to which to sign a contract or to make an investment decision.

Sopharma AD is not responsible neither for decisions and actions taken based on the content of the information from this meeting nor for damages caused as a result of such actions and decisions.

The information, statements and opinions submitted at this meeting are for information purposes only and do not constitute a public offer under any applicable legislation or an offer for sale or solicitation for an offer for the purchase or subscribe of securities or financial instruments or any advice or recommendation with respect to such securities or other financial instruments. None of the securities referred to herein have been or will be, registered under the US Securities Act 1933 or any subsequent amendments, or under the securities laws of any state or other jurisdiction of the United States or in Australia, Canada or Japan or in any other country where such an offer or invitation would be illegal (the "other countries") and there will be no public offering of such securities in the United States. This information does not constitute or form part of any offer or solicitation to purchase or subscribe for securities in the United States or other countries.

Neither the Company, nor any member of the management of Sopharma AD, nor any of its representatives, directors or employees, accepts any liability whatsoever with connection with the information provided at this meeting or in relation to any loss from its use or from any relince placed on it. "

At the meeting, Sopharma AD, Sopharma Group and Sopharma Trading AD were introduced by short presentations about the financial results for the first nine months of 2017.

During the discussion session, a number of questions were asked, as a result of which the companies provided explanations regarding the following main areas of their activity:

1. Capital Investments - Sopharma AD announced that currently have been made decisions for exploring the possibilities for construction of two production facilities - in Kazanlak - extraction power and in Sofia new lyophilic production.

2. The registration of the product TABEX in the USA - Mr. Donev announced that at this stage, details are still unknown, as the start of clinical tests will begin in 2018.

3. Optimization, improvement of the operating result - Mr. Donev replied that this is mainly due to the optimization of the processes in the Group and in the Company, which continue with the intentions of the merger of Unipharm AD, whose documents are subject of approval by the FSC. In addition, Mr. Donev mentioned the projects for renovation of "Momina krepost" AD with European funds, which will allow the company to be more competitive and to offer better products.

4. External Markets - The new, rapidly growing but small-scale markets like Vietnam and the improvement of the macroeconomic environment in Russia and Ukraine were mentioned.

5. Shareholder Structure - Mr. Donev commented that at a meeting with the management of Romfarm, that he was allowed to cite, it was shared that Rompharm had left their trusted management package and that they were not the initiators of the recent actions during the last few months, as well as that they did not intend to go below the price of 4.27 BGN.

6. Sopharma Group - Mr. Dimitrov commented on the state of the Serbian market, namely that its maturity determines the possibility of big growth, as it was in Bulgaria about 10 years ago. Sopharma Trading AD considers that Lekovit's post-acquisition phase is going very well and that the plans for the Group, while preserving the macroeconomic framework, are at least doubling sales revenue over the next three years.

7. Retail at Sopharma Trading AD - questions about the "SOpharmacy" chain and its development, Mr. Dimitrov replied that all pharmacies grow faster than the market.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD notifies that for October 2017 the Company recorded an increase of sales revenues of 7% compared to the same month of 2016, including 3% increase of domestic sales and 12% increase of export sales.

For the first ten months of this year, revenues from sales increased by 12% compared to the same period of 2016, including 2% decrease of domestic sales and a 23% increase of export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

INDIVIDUAL FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 September 2017

1. Financial Statements

2. Notes to the Financial Statements

3. Management report

4. Templates of the financial reports approved by the Bulgarian FSC

5. Declaration of the responsible directors

6. Insiders' information

7. Additional information

8. List of insider information under Art. 7 of Regulation (EU) 596/2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

NOTIFICATION

We would like to notify that on November 3 2017 (Friday) Sopharma AD organizes an Annual Meeting with Investors, on which the Sopharma AD and Sopharma Trading AD will present the main goals achieved and the new challenges. The meeting will take place in the Conference center of Sopharma Business Towers, Sofia. We kindly request that all interested parties notify us not later than October 20 2017 by e-mail irevents@sopharma.bg or by telephone +3592 8134 319 in order to receive their registration forms. Places are limited.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD notifies that for September 2017 the Company recorded an increase of sales revenues of 8% compared to the same month of 2016, including 1% decrease of domestic sales and 11% increase of export sales.

For the first nine months of this year, revenues from sales increased by 16% compared to the same period of 2016, including 2% increase of domestic sales and a 25% increase of export sales. After the merger of Medica AD, from the beginning of the year the Company recorded an increase of sales revenues of 25%, including 29% increase of export sales and 19% increase of domestic sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:

Date of the transaction Operation Number of shares Unit price (BGN)

28.09.2017 Sale 400 4.3900

28.09.2017 Sale 100 4.3900

28.09.2017 Sale 500 4.3900

28.09.2017 Sale 500 4.3900

28.09.2017 Sale 234 4.3900

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

SOPHARMA AD hereby informs that on 26 September 2017 the Company bought 1000 own shares representing 0.00074% of the share capital of the Company, at a total value of 4400.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.4 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 160 761, representing 3.83 % of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:

Date of the transaction Operation Number of shares Unit price (BGN)

27.09.2017 Buy 500 4.3900

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD notifies that in conjunction with the tender offering made on the grounds of Art. 149 para. 6 of the Public Offering of Securities Act and the right of the shareholders who have not accepted the offer under Art. 157b, we provide information for the fulfillment of the obligation of Sopharma AD under this Article:

1. The offeror has bought a total of 125 530 shares with voting right of Unipharm AD;

2. 17 shareholders have applied for share buy-back under the right given to them by Art. 157b of POSA.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:

Date of the transaction Operation Number of shares Unit price (BGN)

26.09.2017 Sale 850 4.4000

26.09.2017 Sale 111 4.4300

26.09.2017 Sale 26 4.4300

26.09.2017 Sale 363 4.4300

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

SOPHARMA AD hereby informs that on 21 September 2017 the Company bought 6635 own shares representing 0.0049% of the share capital of the Company, at a total value of 28750.33.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.33 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 159 761, representing 3.83 % of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

21.09.2017 Sale 700 4.3100

21.09.2017 Sale 300 4.3100

21.09.2017 Sale 1 000 4.3600

21.09.2017 Sale 1 000 4.3600

21.09.2017 Sale 500 4.3600

21.09.2017 Sale 115 4.3450

21.09.2017 Sale 885 4.3450

21.09.2017 Sale 500 4.3010

21.09.2017 Sale 126 4.3000

21.09.2017 Sale 174 4.3000

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:

Date and time of the transaction Operation Number of shares Unit price (BGN)

20.09.2017 Sale 4.290 150

20.09.2017 Sale 4.290 100

20.09.2017 Sale 4.330 500

20.09.2017 Sale 4.301 150

20.09.2017 Sale 4.301 1 850

20.09.2017 Sale 4.301 750

20.09.2017 Sale 4.330 500

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

SOPHARMA AD hereby informs that from 20 September 2017 the Company bought 5650 own shares representing 0.0042% of the share capital of the Company, at a total value of 24 441.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.33 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 153 126, representing 3.82 % of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:

Date of the transaction Operation Number of shares Unit price (BGN)

20.09.2017 Sale 50 4.3000

20.09.2017 Sale 50 4.3000

20.09.2017 Sale 100 4.2910

20.09.2017 Sale 104 4.3010

20.09.2017 Sale 150 4.3100

20.09.2017 Sale 150 4.3100

20.09.2017 Sale 1 000 4.3300

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD notifies that from 18 September 2017 up to and including 19 September 2017 Sopharma AD acquired 12 927 shares from the capital of Unipharm AD as a result of filed requests under the provisions of art. 157b from the LOPS.

The term under art. 157b expired on 19 September 2017.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:

Date of the transaction Operation Number of shares Unit price (BGN)

19.09.2017 Buy 1 000 4.1400

19.09.2017 Buy 695 4.1400

19.09.2017 Buy 305 4.1400

19.09.2017 Buy 200 4.1300

19.09.2017 Sale 600 4.2450

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

18.09.2017 Buy 408 4.2100

18.09.2017 Buy 4 000 4.2100

18.09.2017 Buy 592 4.2100

18.09.2017 Buy 5 533 4.2000

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:

Date and time of the transaction Operation Number of shares Unit price (BGN)

14.09.2017 Buy 151 4.410

15.09.2017 Buy 200 4.380

15.09.2017 Buy 500 4.330

18.09.2017 Buy 3 000 4.280

18.09.2017 Buy 1 312 4.230

18.09.2017 Buy 180 4.230

18.09.2017 Buy 1 000 4.230

18.09.2017 Buy 1 508 4.230

18.09.2017 Buy 382 4.220

18.09.2017 Buy 5 218 4.220

18.09.2017 Buy 2 000 4.210

18.09.2017 Buy 1 272 4.200

18.09.2017 Buy 4 328 4.200

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD notifies that on 18 September 2017 Sopharma AD acquired 345 shares from the capital of Unipharm AD as a result of filed requests under the provisions of art. 177b from the LOPS.

We kindly remind all shareholders of Unipharm AD who did not take part in the tender offering extended by Sopharma AD that they have the right to that their shares be redeemed until 19 September 2017. The request must be in writing and contain information about the shareholder and the shares he owns. The request should be addressed to the authorized investment intermediary Elana Trading AD. The price per share of Unipharm AD for the offer under Art. 157a and in exercising the rights of the shareholders under Art. 157b, in accordance with the provisions of Art. 157a, para. 3 is equal to the price of the offered offering of 4.35 BGN per share.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

SOPHARMA AD hereby informs that from 15 September 2017 up to and including 18 September 2017 the Company bought 10 600 own shares representing 0.0079% of the share capital of the Company, at a total value of 44 878.01 BGN on the Bulgarian Stock Exchange, the average price per share was 4.23 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 329 317, representing 3.95 % of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

SOPHARMA AD hereby informs that 15 September 2017 the Company bought 15 695 own shares representing 0.011% of the share capital of the Company, at a total value of 67 954.41 BGN on the Bulgarian Stock Exchange, the average price per share was 4.33 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 318 717, representing 3.95 % of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:

Date and time of the transaction Operation Number of shares Unit price (BGN)

12.09.2017 Buy 1 000 4.5000

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD hereby informs that from 12 September 2017 up to and including 14 September 2017 the Company bought 50 000 own shares representing 0.037% of the share capital of the Company, at a total value of 222 085.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.44 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 303 022, representing 3.93 % of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

12.09.2017 Buy 2 000 4.5000

12.09.2017 Buy 120 4.4800

12.09.2017 Buy 100 4.4800

12.09.2017 Buy 1 780 4.4800

13.09.2017 Buy 1 000 4.4600

13.09.2017 Buy 1 000 4.4550

13.09.2017 Buy 2 000 4.3700

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

12.09.2017 Buy 3 000 4.5010

13.09.2017 Buy 200 4.4000

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:

Date and time of the transaction Operation Number of shares Unit price (BGN)

07.09.2017 Buy 3000 4.68

07.09.2017 Buy 1000 4.68

07.09.2017 Buy 1900 4.68

07.09.2017 Buy 100 4.68

08.09.2017 Buy 500 4.607

08.09.2017 Buy 1000 4.596

11.09.2017 Buy 1000 4.565

11.09.2017 Buy 121 4.550

11.09.2017 Buy 379 4.550

12.09.2017 Buy 2000 4.501

13.09.2017 Buy 1000 4.461

13.09.2017 Buy 5000 4.460

13.09.2017 Buy 5000 4.370

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD announces that on 14 September, 2017 in accordance with art. 262e and the following from the Commercial Code Unipharm AD and Sopharma AD signed a contract for transformation through merger of Unipharm AD in Sopharma AD and the respective consequences following that decision. The fair price of the participants in the transformation is based on widely accepted evaluation methods. Based on the fair price the participants in the transformation reached a ratio of exchange of 0. 891512, meaning that one share of Unipharm AD will be exchanged for 0. 891512 shares of Sopharma AD. The companies have hired the services of certified appraisers whose reports are a necessary prerequisite for the filing of the documents for transformation with the FSC. As of this moment the responsible Deputy Chairman of the FSC has not issued an approval in accordance with art. 124 from the LPOS of the transformation contract, of the reports of the BoD according to art. 262k from the Commercial code and the report of the appraiser under art. 262o from the Commercial Code.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

The Board of Directors of Sopharma notifies that it took a decision to initiate a procedure for merging Unipharm AD, VAT number 831537465 based in the city of Sofia on 3, "Trayko Stanoev" Str. into Sopharma AD, under the regulation of the Commercial Code and art. 122 and the following of the Law on Public Offering of Securities and chooses "Elana Trading" AD VAT number 831470130, based on 5, Lachezar Stanchev Str. for a consultant in relation to the merger.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

11.09.2017 Buy 200 4.5800

11.09.2017 Buy 200 4.5700

11.09.2017 Buy 1 000 4.5150

11.09.2017 Buy 570 4.5150

11.09.2017 Buy 200 4.5200

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

11.09.2017 Buy 471 4.5500

11.09.2017 Buy 29 4.5500

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

SOPHARMA AD hereby informs that on 11 September 2017 the Company bought 10 000 own shares representing 0.0074% of the share capital of the Company, at a total value of 45 125.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.51 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 255 102, representing 3.90 % of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:

Date and time of the transaction Operation Number of shares Unit price (BGN)

08.09.2017 Buy 200 4.6450

08.09.2017 Buy 1 000 4.6050

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

8.09.2017 Buy 500 4.6150

8.09.2017 Buy 500 4.6120

8.09.2017 Buy 2 000 4.6050

8.09.2017 Buy 2 615 4.6020

8.09.2017 Buy 385 4.6020

8.09.2017 Buy 200 4.5900

8.09.2017 Buy 200 4.5800

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

08.09.2017 Sale 1 000 4.5960

08.09.2017 Sale 200 4.5900

08.09.2017 Sale 100 4.5900

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD notifies that on 8 September 2017 Sopharma AD acquired 111 066 shares from the capital of Unipharm AD as a result of filed requests under the provisions of art. 177b from the LOPS.

We kindly remind all shareholders of Unipharm AD who did not take part in the tender offering extended by Sopharma AD that they have the right to that their shares be redeemed until 19 September 2017. The request must be in writing and contain information about the shareholder and the shares he owns. The request should be addressed to the authorized investment intermediary Elana Trading AD. The price per share of Unipharm AD for the offer under Art. 157a and in exercising the rights of the shareholders under Art. 157b, in accordance with the provisions of Art. 157a, para. 3 is equal to the price of the offered offering of 4.35 BGN per share.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

7.09.2017 Buy 300 4.6950

7.09.2017 Buy 100 4.6990

7.09.2017 Buy 500 4.7000

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:

Date and time of the transaction Operation Number of shares Unit price (BGN)

01.09.2017 Buy 2000 4.600

01.09.2017 Buy 2000 4.700

01.09.2017 Buy 2000 4.705

01.09.2017 Buy 350 4.720

01.09.2017 Buy 515 4.740

01.09.2017 Buy 485 4.740

01.09.2017 Buy 15 4.720

01.09.2017 Buy 1 000 4.690

01.09.2017 Buy 500 4.690

01.09.2017 Buy 200 4.700

01.09.2017 Buy 500 4.770

01.09.2017 Buy 500 4.790

04.09.2017 Buy 1000 4.77

04.09.2017 Buy 1000 4.765

04.09.2017 Buy 2000 4.745

04.09.2017 Buy 1000 4.72

05.09.2017 Buy 20 4.640

05.09.2017 Buy 700 4.650

05.09.2017 Buy 1000 4.660

05.09.2017 Buy 1000 4.660

05.09.2017 Buy 1000 4.660

05.09.2017 Buy 1000 4.660

05.09.2017 Buy 1000 4.660

05.09.2017 Buy 1000 4.660

05.09.2017 Buy 1000 4.660

05.09.2017 Buy 1000 4.660

05.09.2017 Buy 957 4.660

05.09.2017 Buy 43 4.660

05.09.2017 Buy 612 4.660

05.09.2017 Buy 20 4.660

05.09.2017 Buy 100 4.684

05.09.2017 Buy 2 368 4.660

05.09.2017 Buy 1 000 4.640

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

01.09.2017 Buy 200 4.7000

01.09.2017 Buy 100 4.7000

01.09.2017 Buy 500 4.7450

04.09.2017 Buy 42 4.7600

04.09.2017 Buy 100 4.7610

04.09.2017 Buy 70 4.7610

04.09.2017 Buy 288 4.7600

04.09.2017 Buy 1 000 4.7700

04.09.2017 Buy 1 000 4.7650

04.09.2017 Buy 400 4.7570

04.09.2017 Buy 112 4.7600

04.09.2017 Buy 2 000 4.7450

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

01.09.2017 Buy 500 4.6050

01.09.2017 Buy 5 000 4.6000

01.09.2017 Buy 2 320 4.6000

01.09.2017 Buy 85 4.6500

01.09.2017 Buy 1 915 4.6500

01.09.2017 Buy 2 680 4.6000

01.09.2017 Buy 100 4.7450

01.09.2017 Buy 170 4.7490

01.09.2017 Buy 140 4.7500

01.09.2017 Buy 185 4.7940

01.09.2017 Buy 100 4.7950

01.09.2017 Buy 700 4.7950

01.09.2017 Buy 165 4.7970

01.09.2017 Buy 1 000 4.7980

01.09.2017 Buy 300 4.8000

01.09.2017 Buy 2 961 4.8000

01.09.2017 Buy 574 4.8000

01.09.2017 Buy 160 4.7990

01.09.2017 Buy 1 4.8000

01.09.2017 Buy 1 839 4.8000

01.09.2017 Buy 1 000 4.8050

01.09.2017 Buy 85 4.8000

01.09.2017 Buy 915 4.8000

01.09.2017 Buy 190 4.7500

01.09.2017 Buy 20 4.7400

01.09.2017 Buy 495 4.7400

01.09.2017 Buy 485 4.7400

01.09.2017 Buy 100 4.7000

01.09.2017 Buy 250 4.7190

01.09.2017 Buy 170 4.7440

01.09.2017 Buy 500 4.7450

01.09.2017 Buy 340 4.7790

01.09.2017 Buy 233 4.7800

01.09.2017 Buy 170 4.7870

01.09.2017 Buy 180 4.7890

01.09.2017 Buy 3 000 4.7900

01.09.2017 Buy 407 4.7900

01.09.2017 Buy 3 000 4.7200

01.09.2017 Buy 500 4.7900

01.09.2017 Buy 300 4.7880

01.09.2017 Buy 25 4.7880

01.09.2017 Buy 200 4.7890

01.09.2017 Buy 790 4.7890

01.09.2017 Buy 185 4.7890

01.09.2017 Buy 1 000 4.7500

04.09.2017 Buy 1 000 4.7700

04.09.2017 Buy 2 000 4.7700

04.09.2017 Buy 288 4.7600

04.09.2017 Buy 112 4.7600

04.09.2017 Buy 300 4.7400

04.09.2017 Buy 5 000 4.6500

04.09.2017 Buy 1 000 4.6500

05.09.2017 Buy 300 4.6890

05.09.2017 Buy 300 4.6890

05.09.2017 Buy 300 4.6890

05.09.2017 Buy 300 4.6890

05.09.2017 Buy 500 4.6850

05.09.2017 Buy 434 4.6850

05.09.2017 Buy 500 4.6850

05.09.2017 Buy 800 4.6650

05.09.2017 Buy 200 4.6650

05.09.2017 Buy 700 4.6850

05.09.2017 Buy 300 4.6890

05.09.2017 Buy 300 4.6890

05.09.2017 Buy 100 4.6890

05.09.2017 Buy 300 4.6890

05.09.2017 Buy 300 4.6890

05.09.2017 Buy 200 4.6890

05.09.2017 Buy 31 4.6890

05.09.2017 Buy 269 4.6890

05.09.2017 Buy 400 4.6900

05.09.2017 Buy 700 4.6900

05.09.2017 Buy 585 4.6900

05.09.2017 Buy 40 4.6900

05.09.2017 Buy 271 4.6800

05.09.2017 Buy 735 4.6800

05.09.2017 Buy 1 500 4.6700

05.09.2017 Buy 2 000 4.6650

05.09.2017 Buy 964 4.6400

05.09.2017 Buy 1 000 4.6590

05.09.2017 Buy 500 4.7000

05.09.2017 Buy 230 4.7000

05.09.2017 Buy 770 4.7000

05.09.2017 Buy 66 4.6500

05.09.2017 Buy 270 4.7000

05.09.2017 Buy 230 4.7000

05.09.2017 Buy 3 000 4.7000

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD notifies that for August 2017 the Company recorded an increase of sales revenues of 12% compared to the same month of 2016, including 12% increase of domestic sales and 12% increase of export sales.

For the first eight months of this year, revenues from sales increased by 17% compared to the same period of 2016, including 3% increase of domestic sales and a 27% increase of export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

We hereby notify you that due to technical errors we publish a revised management report of Sopharma Group as at 30 June 2017.

We apologize for the inconvenience.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

1. Financial Statements

2. Notes to the Financial Statements

3. Management report

4. Templates of the financial reports approved by the Bulgarian FSC

5. Declaration of the responsible directors

6. Insiders' information

7. Additional information

8. List of insider information under Art. 7 of Regulation (EU) 596/2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD notifies that on 2 August 2017 Sopharma AD acquired 1537 shares from the capital of Unipharm AD as a result of filed requests under the provisions of art. 177b from the LOPS.

We kindly remind all shareholders of Unipharm AD who did not take part in the tender offering extended by Sopharma AD that they have the right to that their shares be redeemed until 19 September 2017. The request must be in writing and contain information about the shareholder and the shares he owns. The request should be addressed to the authorized investment intermediary Elana Trading AD. The price per share of Unipharm AD for the offer under Art. 157a and in exercising the rights of the shareholders under Art. 157b, in accordance with the provisions of Art. 157a, para. 3 is equal to the price of the offered offering of 4.35 BGN per share.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that " Donev Investments Holding" AD executed the following transactions related to shares in the Company:

Date and time of the transaction Operation Number of shares Unit price (BGN)

01.06.2017 Buy 503000 3.98

06.06.2017 Sale 200 4.305

06.06.2017 Sale 100 4.310

06.06.2017 Sale 1200 4.302

07.06.2017 Sale 1000 4.32

07.06.2017 Sale 1000 4.32

07.06.2017 Sale 500 4.34

07.06.2017 Sale 10 4.34

07.06.2017 Sale 290 4.34

07.06.2017 Sale 218 4.35

07.06.2017 Sale 282 4.35

07.06.2017 Sale 500 4.355

07.06.2017 Sale 1000 4.33

07.06.2017 Sale 1000 4.33

08.06.2017 Sale 1500 4.302

08.06.2017 Sale 290 4.302

08.06.2017 Sale 30 4.302

08.06.2017 Sale 1000 4.302

08.06.2017 Sale 1000 4.302

08.06.2017 Sale 1000 4.302

08.06.2017 Sale 1000 4.302

09.06.2017 Sale 325 4.29

09.06.2017 Sale 100 4.29

09.06.2017 Sale 123 4.29

09.06.2017 Sale 277 4.29

12.06.2017 Sale 45 4.35

12.06.2017 Sale 205 4.35

12.06.2017 Sale 159 4.40

12.06.2017 Sale 340 4.40

12.06.2017 Sale 1 4.40

13.06.2017 Sale 150 4.395

15.06.2017 Buy 300 4.25

16.06.2017 Sale 245 4.315

16.06.2017 Sale 100 4.315

16.06.2017 Sale 155 4.315

16.06.2017 Sale 245 4.315

16.06.2017 Sale 100 4.315

16.06.2017 Sale 155 4.315

16.06.2017 Sale 100 4.340

16.06.2017 Sale 100 4.340

30.06.2017 Buy 100 4.552

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD notifies that the transformation through merger of Medika AD in Sopharma AD has been registered with the Commercial Register with number 20170808155501.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD notifies that for July 2017 the Company recorded an increase of sales revenues of 17% compared to the same month of 2016, including 2% increase of domestic sales and 25% increase of export sales.

For the first seven months of this year, revenues from sales increased by 18% compared to the same period of 2016, including 1% increase of domestic sales and a 30% increase of export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD notifies that the merger between Achieve Life Sciences, Inc. and OncoGenex Pharmaceuticals was successfully closed today and as a result of which the stockholders of Achieve have become the majority stockholders of OncoGenex. OncoGenex has been renamed Achieve Life Sciences (NASDAQ: ACHV).

The company announced that "Cytisine is a drug of global public health importance and the transition of Achieve to the public markets is a critical step in advancing our development program," commented Rick Stewart, Chairman and CEO of Achieve Life Science.

The whole press release may be found at http://ir.oncogenex.com/releasedetail.cfm?ReleaseID=1030091.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD notifies that the stabilization of the economic environment on our main export markets and the optimization of the operations of Sopharma AD led to 73% increase of the operating profit from BGN 14 310 thousand for the first half of 2016 BGN 24 698 thousand for the first half of 2017 and of 50% increase of EBITDA from BGN 21 318 thousand for the fisrst half of 2016 to BGN 32 048 thousand for the first half of 2017.

"Our efforts towards improving the way we operate, to further improve the synergy after the merger with Bulgarian Rose - Sevtopolis AD, to optimize or trade activities and to start new, interesting and profitable projects are reconfirmed in our financial results. We also appereciate the fact that factors outside of our control also improved leading to fast growth. We are proud that our subsidiary Sopharma Trading AD received a green light from to start larger projects in Serbia.", comments Ognian Donev, PhD, Executive director and Chariman of the Board of directors of Sopharma AD.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

INDIVIDUAL FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 June 2017

1. Financial Statements

2. Notes to the Financial Statements

3. Management report

4. Templates of the financial reports approved by the Bulgarian FSC

5. Declaration of the responsible directors

6. Insiders' information

7. Additional information

8. List of insider information under Art. 7 of Regulation (EU) 596/2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

We would like to notify that "Sopharma" AD acquired 75% from the capital of the successful start-up for development and registration of food additives "Aromania" (www.arolife.bg).

For the nearly two years since its establishment "Aromania" has more than 20 registered products and for 12 of them the company either has or has flied a different form of patent protection - trade mark, industrial design or useful model. Two of the products are leaders in their categories. For 2016 the revenues from sales of the company are 1,279 thousand BGN.

Sopharma will use this platform for a wider presence on the food additives market and to proudly enter the society of the "Bulgarian business angels".

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

We would like to notify that in interest of its shareholders Sopharma AD will initiate dividend payment of the voted on the AGM held on 2 June 2017 dividend of 0.10 BGN earlier than planned on 24 July 2017.

The persons eligible for dividend are those present in the register of the Central Depository 14 days after the date of the AGM, i.e. 16 June 2017.

In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD notifies that for June 2017 the Company recorded an increase of sales revenues of 31% compared to the same month of 2016, including 2% decrease of domestic sales and 59% increase of export sales.

For the first six months of this year, revenues from sales increased by 18% compared to the same period of 2016, including 1% increase of domestic sales and a 30% increase of export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

NOTIFICATION OF INSIDERS' TRANSACTIONS

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

28.6.2017 10:13 Buy 200 4.4650

28.6.2017 10:14 Buy 1 800 4.4650

28.6.2017 10:22 Buy 234 4.4990

28.6.2017 10:22 Buy 69 4.4990

28.6.2017 10:22 Buy 470 4.4990

28.6.2017 10:22 Buy 427 4.5000

28.6.2017 10:22 Buy 1 000 4.5000

28.6.2017 10:36 Buy 250 4.5290

28.6.2017 10:36 Buy 750 4.5300

28.6.2017 10:42 Buy 1 000 4.5400

28.6.2017 10:57 Buy 624 4.5500

28.6.2017 10:57 Buy 376 4.5500

29.6.2017 10:42 Buy 400 4.5500

29.6.2017 10:46 Buy 1 000 4.5310

30.6.2017 10:44 Buy 1 000 4.5000

30.6.2017 10:44 Buy 848 4.5000

30.6.2017 10:49 Buy 152 4.5000

30.6.2017 10:55 Buy 600 4.5000

30.6.2017 15:31 Buy 2 000 4.5000

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

26.6.2017 10:22 Buy 2 000 4.4000

26.6.2017 10:28 Buy 280 4.4000

26.6.2017 12:27 Buy 200 4.4000

26.6.2017 13:20 Buy 300 4.4000

26.6.2017 13:30 Buy 500 4.4000

26.6.2017 13:31 Buy 124 4.4000

26.6.2017 13:50 Buy 376 4.4000

26.6.2017 15:23 Buy 300 4.4400

26.6.2017 16:24 Buy 190 4.4400

26.6.2017 16:24 Buy 363 4.4470

26.6.2017 16:42 Buy 100 4.4470

26.6.2017 16:42 Buy 47 4.4470

26.6.2017 17:00 Buy 100 4.4480

26.6.2017 17:00 Buy 300 4.4480

27.6.2017 10:14 Buy 100 4.4500

27.6.2017 10:22 Buy 4 200 4.4500

27.6.2017 12:37 Buy 100 4.4920

27.6.2017 15:56 Buy 250 4.4650

27.6.2017 15:58 Buy 250 4.4890

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

22.06.2017 Buy 150 4.4330

22.06.2017 Buy 600 4.4000

22.06.2017 Buy 490 4.4000

22.06.2017 Buy 400 4.4000

22.06.2017 Buy 1 000 4.4000

22.06.2017 Buy 320 4.4000

22.06.2017 Buy 500 4.4000

22.06.2017 Buy 180 4.4000

22.06.2017 Buy 795 4.4000

22.06.2017 Buy 205 4.4000

22.06.2017 Buy 1 000 4.4000

22.06.2017 Buy 1 000 4.4000

23.06.2017 Buy 220 4.3990

23.06.2017 Buy 300 4.4000

23.06.2017 Buy 200 4.4100

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

16.06.2017 Buy 100 4.3150

16.06.2017 Buy 60 4.3160

16.06.2017 Buy 40 4.3160

16.06.2017 Buy 200 4.3000

16.06.2017 Buy 120 4.3200

16.06.2017 Buy 60 4.2950

16.06.2017 Buy 200 4.3190

16.06.2017 Buy 100 4.3400

20.06.2017 Buy 500 4.4200

20.06.2017 Buy 100 4.4580

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

On the grounds of Art. 157 of POSA in connection with Art. 154 of the Public Offering of Securities Act and in connection with the expired deadline for acceptance of the tender offer submitted by Sopharma AD to the shareholders of Unipharm AD, we inform you about the results of the tender offering submitted by Sopharma AD for the purchase of the shares of the other shareholders of Unipharm AD.

Company, object of the offer: Unipharm AD, with management address Sofia 1797, Studentski grad, zh.k. Darvenitsa, Trayko Stanoev Str.

Tender offeror: Sopharma AD, with address: Sofia, Nadezhda district, 16, Iliensko shose Str.

Authorized investment intermediary: Elana Trading AD, with management address: Sofia, Sredets, 4, Kuzman Shapkarev Str., and license issued by FSC for carrying out activity as an investment intermediary on the basis of Decision No. 171 -IP / 08.03.2006

Price offered per share: BGN 4.35 (four leva thirty-five stotinki) Number of persons accepted the tender offer: 65 Shareholder with total number of shares: 1 125 021, representing 18.75% of the capital of Unipharm AD.

As a result of the tender offer and after the conclusion of the transactions with the shareholders that have accepted it, Sopharma AD will directly own 96.63% of the shares of Unipharm AD. Sopharma AD has the right, within three months from the closing date of the tender offer, to submit, after obtaining the approval of the FSC, an offer for the purchase of the shares of the remaining shareholders of Unipharm AD on the grounds of Art. 157a of POSA. In addition, according to the provisions of Art. 157b of the POSA, each shareholder is entitled to require from Sopharma AD to redeem his/her shares until 19 September 2017. The request must be in writing and contain information about the shareholder and the shares he owns. The request should be addressed to the authorized investment intermediary Elana Trading AD. The price per share of Unipharm AD for the proposal under Art. 157a and in exercising the rights of the shareholders under Art. 157b, in accordance with the provisions of Art. 157a, para. 3 is equal to the price of the tender offering of BGN 4.35 per share.

The results of the tender offering were published by the tender offeror in the newspapers "Capital Daily" and "Sega" as of 21.06.2017.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

14.06.2017 Buy 100 4.37

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

15.06.2017 Buy 100 4.2890

15.06.2017 Buy 200 4.3100

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:

Date and time of the transaction Operation Number of shares Unit price (BGN)

12.06.2017 Buy 500 4.3600

13.06.2017 Buy 100 4.3750

13.06.2017 Buy 70 4.3900

13.06.2017 Buy 30 4.3900

14.06.2017 Buy 100 4.4000

14.06.2017 Buy 250 4.4000

14.06.2017 Buy 120 4.3810

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

We are pleased to announce that the next step in the process of merging Achieve Lifesciences and Oncogenex has been completed with the approval of the merger by the US SEC. OncoGenex will hold a special shareholder meeting on 1 August 2017 to vote the merger. Shortly after the newly formed entity will trade on NASDAQ stock exchange under the ticker symbol ACHV.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

13.06.2017 Buy 800 4.4100

13.06.2017 Buy 22 4.4100

13.06.2017 Buy 178 4.4100

13.06.2017 Buy 200 4.3900

13.06.2017 Buy 350 4.3900

13.06.2017 Buy 250 4.3900

14.06.2017 Buy 50 4.4000

14.06.2017 Buy 50 4.4000

14.06.2017 Buy 100 4.4000

14.06.2017 Buy 700 4.4000

14.06.2017 Buy 150 4.4000

14.06.2017 Buy 650 4.4000

14.06.2017 Buy 57 4.3800

14.06.2017 Buy 23 4.3700

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

12.06.2017 Buy 300 4.3720

13.06.2017 Buy 700 4.41

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

12.06.2017 Buy 4.3200 27

12.06.2017 Buy 4.3710 324

12.06.2017 Buy 4.3710 26

12.06.2017 Buy 4.4000 263

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

09.06.2017 Buy 191 4.2760

09.06.2017 Buy 59 4.2760

09.06.2017 Buy 100 4.2900

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

We would like to notify that Sopharma AD will initiate dividend payment of the voted on the AGM held on 2 June 2017 dividend of 0.10 BGN on 21 August 2017.

The persons eligible for dividend are those present in the register of the Central Depository 14 days after the date of the AGM, i.e. 16 June 2017.

In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

08.06.2017 Buy 10 4.302

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:

Date and time of the transaction Operation Number of shares Unit price (BGN)

08.06.2017 Buy 100 4.3000

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that pursuant to art. 3, para 26a and art.19, para 1a from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs Rosica Doneva, person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors that she, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

05.06.2017 Buy 2000 4.269

06.06.2017 Buy 1 850 4.3

06.06.2017 Buy 150 4.3

06.06.2017 Buy 1 000 4.3

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:

Date and time of the transaction Operation Number of shares Unit price (BGN)

05.06.2017 Buy 765 4.3000

05.06.2017 Buy 150 4.3000

05.06.2017 Buy 85 4.3000

05.06.2017 Buy 1 000 4.2810

05.06.2017 Buy 100 4.2700

07.06.2017 Buy 500 4.2950

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD (the "Company") announces that on 7 June 2017 the Company received a notification for the acquisition of 503 000 shares, representing 0.37% of its capital, by "Donev investments holding" AD. After the transaction, the share of "Donev investments holding" AD in the capital of Sopharma AD reached 25.15%.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

05.06.2017 Buy 125 4.3680

05.06.2017 Buy 125 4.3680

05.06.2017 Buy 125 4.3680

05.06.2017 Buy 125 4.3680

05.06.2017 Buy 125 4.3680

05.06.2017 Buy 125 4.3680

05.06.2017 Buy 125 4.3680

05.06.2017 Buy 125 4.3680

05.06.2017 Buy 80 4.3690

05.06.2017 Buy 500 4.3700

05.06.2017 Buy 2 420 4.3750

05.06.2017 Buy 850 4.3650

05.06.2017 Buy 850 4.3650

05.06.2017 Buy 850 4.3650

05.06.2017 Buy 450 4.3650

05.06.2017 Buy 3 000 4.3200

05.06.2017 Buy 3 000 4.3200

05.06.2017 Buy 150 4.3200

05.06.2017 Buy 850 4.3200

05.06.2017 Buy 200 4.3020

05.06.2017 Buy 300 4.3020

05.06.2017 Buy 3 000 4.3000

05.06.2017 Buy 1 000 4.2990

05.06.2017 Buy 2 000 4.3000

05.06.2017 Buy 1 750 4.3000

05.06.2017 Buy 650 4.3000

05.06.2017 Buy 1 000 4.3000

05.06.2017 Buy 500 4.3000

05.06.2017 Buy 500 4.3000

05.06.2017 Buy 50 4.3000

05.06.2017 Buy 1 000 4.2700

05.06.2017 Buy 2 000 4.2600

05.06.2017 Buy 254 4.2800

05.06.2017 Buy 137 4.2500

05.06.2017 Buy 200 4.2800

05.06.2017 Buy 4 4.2800

05.06.2017 Buy 50 4.2400

05.06.2017 Buy 54 4.2800

07.06.2017 Buy 1 000 4.3200

07.06.2017 Buy 201 4.3300

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

01.06.2017 Buy 7 500 3.9810

01.06.2017 Buy 7 000 3.9810

01.06.2017 Buy 7 000 3.9800

01.06.2017 Buy 7 000 3.9800

01.06.2017 Buy 7 000 3.9800

01.06.2017 Buy 900 4.0300

01.06.2017 Buy 500 4.0480

01.06.2017 Buy 500 4.0480

01.06.2017 Buy 500 4.0490

01.06.2017 Buy 500 4.0490

01.06.2017 Buy 50 4.0410

01.06.2017 Buy 100 4.0410

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 2 JUNE 2017

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 2 JUNE 2017

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

For the first five months of this year, revenues from sales increased by 15% compared to the same period of 2016, including 2% increase of domestic sales and 25% increase of export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Jak podano, dzień dywidendy ustalono na 14 dni od daty walnego zgromadzenia, a jej wypłata ma nastąpić w terminie trzech miesięcy.

W 2016 roku spółka wypłaciła 0,07 BGN dywidendy na akcję. (PAP Biznes)

sar/ osz/

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD hereby notifies all shareholders of the Company about the decision of the AGM of Sopharma AD that took place on June 2th, 2017 regarding the amount and type of dividend distributed and the terms and conditions for its distribution:

AGM approves the proposal by the Board of Directors for the distribution of dividend at the amount of 0.10 BGN /ten stotinki/ per share with dividend right.

The persons eligable for dividend are those present in the register of the Central Depository 14 days after the day of the AGM on which the Annual Financial Report was approved and the decision for dividend was taken.

After the exact amount of the dividend has been determined, based on a list of shareholders, provided. In accordance with the Regulations of the Central Depository, the dividend shall be paid out as follows: for shareholders with client accounts at an investment intermediary - through the investment intermediary, for shareholders without accounts at an investment intermediary - through the branches of Eurobank EFG - Bulgaria AD /Postbank/ in the country. Payment of dividend will commence within three months from the date of the AGM, on which the payment of dividend was approved.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

1. Financial Statements

2. Notes to the Financial Statements

3. Management report

4. Templates of the financial reports approved by the Bulgarian FSC

5. Declaration

6. Annex 9

7. Additional information

8. List of insider information of reg. 596(EU)/2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD notifies that regarding listing of additional issues on the agenda of the Annual General Meeting of Shareholders of Sopharma AD, scheduled for 02.06.2017, we present an updated invitation. Materials related to the new issues are published together with the other materials for the meeting on 02.06.2017

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

For the first four months of this year, revenues from sales increased by 12% compared to the same period of 2016, including 1% increase of domestic sales and 18% increase of export sales.

Please, make the above information public.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Dear Shareholders,

Тhe invitation for the Annual General Meeting of shareholders of Sopharma AD convened for 2 June, 2017 published in x3news, investor.bg and the website of the company www.sopharmagroup.bg contains a technical mistake concerning the second date for the AGM, which is announced in case of lack of quorum on 2 June 2017:

In the first paragraph of the invitation the listed second date is 16 July 2017 and in the last paragraph the listed second date is 16 June 2017.

We would hereby like to advise all shareholders that the correct second date under the conditions of art. 227, para 3 of the Commercial code for the Annual General Meeting of shareholders of Sopharma AD is 16 June 2017.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

Invitation for Annual General Meeting of the Shareholders of Sopharma AD and materials.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

ANNUAL AUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2016

1. Financial Statements

2. Notes to the Financial Statements

3. Management report

4. Templates of the financial reports approved by the Bulgarian FSC

5. Auditors' report

6. Corporate governance declaration

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

1. Financial Statements

2. Notes to the Financial Statements

3. Management report

4. Templates of the financial reports approved by the Bulgarian FSC

5. Declaration of the responsible directors

6. Insider information

7. Additional information

8. List of insider information under Art. 7 of Regulation (EU) 596/2014

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD (the "Company") notifies that on 25 April 2017 the Financial Supervision Commission approved the Contract for transformation through merger and the additional annex to it, signed on 31 January 2017 between Sopharma AD, hereinafter referred to as "Acquirer" and Medica AD, hereinafter referred to as "Acquiree" in accordance with the requirements of art. 262d and following of the Commercial Act (CA). As a result the assets of Medica AD shall be transferred to Sopharma AD and the latter shall become its legal successor. Medica AD will be terminated without liquidation. The Financial Supervision Commission also approved the reports of the management of the two companies, prepared in accordance with the regulations of art.262i of the CA and the reports of the appointed examiners of the participants in the transformation under art. 262M of the CA from 13 October 2014.

As a result of the merger, all shareholders of the Acquiree Medica AD, with the exception of the Acquirer Sopharma AD, which is also a shareholder of the Acquiree, will receive shares of Sopharma AD and become shareholders of it. Against one share of Medica AD each shareholder pursuant to art. 261b, art. 1 of the CA shall receive 0.8813 shares of the capital of Sopharma AD.

The merger is subject to approval by the shareholders of the two companies on the respective General Meetings.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

MINUTES OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF SOPHARMA AD - SOFIA, 24 APRIL 2017

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD (the "Company") hereby notifies all shareholders of the Company, that the Extraordinary General Meeting, convened by the Board of Directors for 24 April 2017 at 11:00 will take place at Sopharma Business Towers, Building B, floor 3, 5 Lachezar Stanchev Str.. The registration begins at 9:30.

All shareholders of the company are invited to participate at the General Meeting in person or by proxy.

As a prerequisite for the technical provisioning of the Extraordinary General Meeting of Shareholders, copies of all letters of attorney must be presented to the Company on paper or electronically at mdnedkova@sopharma.bg by the end of the workday preceding the date of the AGM, namely 5 p.m. on 21 April 2017.

We would like to thank all shareholders for their understanding and cooperation.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD notifies that after receiving a permission from the Moldova Competition Commission, Sopharma AD acquired 51% of the Moldova pharmaceutical distributor RAP Pharma International.

RAP PHARMA INTERNATIONAL (RAP) was established in 2004 and in 2014 started its activities in the pharmaceutical sector after receiving a license for pharmaceutical wholesaling and distribution. Currently the company owns 10 pharmacies and is the most intensively developing company in the Republic of Moldova. The revenues of the company for 2016 increased with almost 40% to 3 million EUR. The company has 79 employees and is one of the 7 distributors in Moldova owning a pharmacies network. The retail market in Moldova for 2016 according to Pharmexpert is about 100 million EUR (a precise statistics is not available). Currently the company is a distributor of the products of Sopharma AD, Medica AD, Momina krepost AD, STADA, GRINDEX - Baltics, POLPHARMA, LEKPHARM - Belarus, FARMA PRIM - Moldova, FLUMED FARM - Moldova, BALKAN PHARMACEUTICALS - Moldova etc.. Since 2016 RAP Pharma is added in the list of companies supplying medicinal products to the State Hospitals in the Republic of Moldova through a centralized tender.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD (the "Company") hereby notifies that on 5 April 2017 Sopharma AD received a decision from the Commission for Protection of Competition that the acquisition of shares of the capital of Doverie Obedinen Holding AD is not subject to preliminary notification under art. 24, para 2 from the Law on Competition at this stage.

Sopharma AD will undertake the respective actions once it reaches the thresholds requiring a tender offering to the remaining shareholders of Doverie Obedinen Holding AD.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

For the first quarter of this year, revenues from sales increased by 12% compared to the same period of 2016, including 4% decrease of domestic sales and 24% increase of export sales.

"Sales on the Russian market in March reassert the uptrend since the beginning of the year and are a real indicator of improving the economic situation. At present, our forecast are that export sales will grow also over the next few months.", said Ognian Donev, PhD, Executive Director and Chairman of the Board of Directors of "Sopharma" AD.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

ANNUAL AUDITED INDIVIDUAL FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2016

1. Financial Statements

2. Notes to the Financial Statements

3. Management report

4. Templates of the financial reports approved by the Bulgarian FSC

5. Declaration of the responsible directors

6. Auditors' report

7. Report regarding the application of the remuneration policy

8. Corporate governance declaration

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD (the "Company") notifies that on 20 March 2017 Sopharma AD, Sofia, UIC 831902088 and Medica AD, Sofia, UIC 000000993 signed an annex to the Contract for transformation through merger reflecting the comments by the FSC. All documents will be filed with the FSC for approval pursuant to art. 124, par. 1 of the Public Offering of Securities Act (POSA) after an independent certified evaluator prepares a report.

As a result of the merger, all shareholders of the transferring company Medica AD, with the exception of the receiving company Sopharma AD, which is also a shareholder of the transferring company, will receive shares of Sopharma AD and become shareholders of it. Against one share of Medica AD each shareholder pursuant to art. 261b, app. 1 of the CA shall receive 0.8831 treasury shares of the capital of Sopharma AD. All other conditions concerning the merger procedure are included in the Contract.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Extraordinary General Meeting of the Shareholders of Sopharma AD

1. Invitation to the Extraordinary General Meeting of Shareholders of Sopharma AD, 24 April 2017

2. Minutes of the Meeting of the Board of Directors of Sopharma AD

3. Substantiated report

4. Letter of Attorney - Sample

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD announces that Sopharma AD received a final prohibition from the Bulgarian Financial Supervision Commission (FSC) to extend a tender offering to the shareholders of Unipharm AD. Sopharma AD is preparing a new tender offering which reflects the comments of the FSC.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

For the first two months of this year, revenues from sales increased by 8% compared to the same period of 2016, including 5% decrease of domestic sales and 16% increase of export sales.

"We are very pleased with the results on the Russian market from the begining of this year and the trend is strenghteining in February reaching 40% increase in export sales.

We are hopeful also with regards to the registration of our product Tabex in the USA. After the news about the merger of Achieve and OncoGenex the good news continue. You can read more abou the cooperation of Achieve with NIH here: www.oncogenex.com.

The preliminary consolidated report of Sopharma Group for 2016 shows that even though the period was relatively difficult on our foreign markets, we still managed to reach a satisfactory EBITDA of 70 million BGN and a net profit of a little bit more than 50 million BGN. Analysis of the main indicators shows improved profitability due to optimization of main expenses and in the light of a maximum market price of a bit over 3 BGN for the year P/E is 8.31 and ROE is 10.9% compared to 5.3% for 2015.", says Mr. Ognian Donev, PhD, CEO and Chairman of the Board of directors of Sopharma AD.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

For the first two months of this year, revenues from sales increased by 8% compared to the same period of 2016, including 5% decrease of domestic sales and 16% increase of export sales.

"We are very pleased with the results on the Russian market from the begining of this year and the trend is strenghteining in February reaching 40% increase in export sales.

We are hopeful also with regards to the registration of our product Tabex in the USA. After the news about the merger of Achieve and OncoGenex the good news continue. You can read more abou the cooperation of Achieve with NIH here:

The preliminary consolidated report of Sopharma Group for 2016 shows that even though the period was relatively difficult on our foreign markets, we still managed to reach a satisfactory EBITDA of 70 million BGN and a net profit of a little bit more than 50 million BGN. Analysis of the main indicators shows improved profitability due to optimization of main expenses and in the light of a maximum market price of a bit over 3 BGN for the year P/E is 8.31 and ROE is 10.9% compared to 5.3% for 2015.", says Mr. Ognian Donev, PhD, CEO and Chairman of the Board of directors of Sopharma AD.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

PRELIMINARY ANNUAL CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2016

1. Financial Statements

2. Notes to the Financial Statements

3. Management report

4. Templates of the financial reports approved by the Bulgarian FSC

5. Declaration

6. Annex 9

7. Additional Information

8. List of insider information

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD announces that the Competition Council of The Republic of Moldova allows the acquisition of over 51% of RAP Pharma International SRL by Sopharma AD.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD (the "Company") notifies that on 13 February 2017 the Contract for merger, as well as reports of the management bodies of the companies involved in the transformation of the company under art. 262i of the CA and the report of the examiner under art. 262m of the CA for transformation through merger between Sopharma AD, Sofia, UIC 831902088 and Medica AD, Kazanluk, UIC 000000993 were filed with the FSC for approval pursuant to art. 124, par. 1 of the Public Offering of Securities Act (POSA). As a result of the merger, all assets of Medica AD shall be transferred to Sopharma AD and the latter shall become its legal successor. Medica AD shall be terminated without liquidation.

As a result of the merger, all shareholders of the transferring company Medica AD, with the exception of the receiving company Sopharma AD, which is also a shareholder of the transferring company, will receive shares of Sopharma AD and become shareholders of it. Against one share of Medica AD each shareholder pursuant to art. 261b, app. 1 of the CA shall receive 0.9486 treasury shares of the capital of Sopharma AD. All other conditions concerning the merger procedure are included in the Contract.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

For the first month of this year, revenues from sales decreased by 4% compared to the same period of 2015, including 5% decrease of domestic sales and 4% decrease of export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD announces that on 31 January, 2017 in accordance with art. 262e and the following from the Commercial Code Medica AD and Sopharma AD signed a contract for transformation through merger of Medica AD in Sopharma AD and the respective consequences following that decision. The fair price of the participants in the transformation is based on widely accepted evaluation methods. Based on the fair price the participants in the transformation reached a ratio of exchange of 0.9486, meaning that one share of Medica AD will be exchanged for 0.9486 shares of Sopharma AD. The companies have hired the services of certified appraisers whose report is a necessary prerequisite for the filing of the documents for transformation with the FSC. As of this moment the deputy Chairman "Investment Supervision" has not issued an approval in accordance with art. 124 from the LPOS of the transformation contract, of the reports of the BoD according to art. 262k from the Commercial code and the report of the appraiser under art. 262o from the Commercial Code.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

FINANCIAL STATEMENTS FOR THE PERIOD ENDING 31 DECEMBER 2016

1. Financial Statements

2. Notes to the Financial Statements

3. Management report

4. Templates of the financial reports approved by the Bulgarian FSC

5. Declaration

6. Insider Information

7. Additional Information

8. List of insider information

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD hereby notifies that the revenues from sales for 2016 decrease with 5% compared to 2015, including 2% decrease in domestic sales mainly due to the overall market price erosion (for the same period the company has a 7% increase in sales in packages) and a 6% decrease in export sales.

"In the past few months we see some signs for economic and political stabilization in Russia, which give us certain security for the results of 2017. We are optimistic for the trend of recovery of the sales in the Ukraine. After the restructuring of our export activities our local teams work systematically for the increase of the results on a number of markets like Poland, Belarus, Latvia, etc. We are very proud with the successful registrations of new products which we are yet to develop. An excellent example is Tuspan - the coughing syrup, which will be available on a number of European markets even this year in case of successful and timely procedures. This year started with a long-awaited news concerning our project of registration of our product Tabex in the USA. In case a restructuring takes place between Achieve and Oncogenex (our remaining shares in the capital of Extab will be transformed in shares in Achieve in case of such restructuring) there will be two advantages for us: first, the new joint team of the two companies will have a much bigger chance of a successful registration of Tabex and second, "Sopharma" AD will become a shareholder in a public company traded on NASDAQ.", says Ognian Donev, PhD, Executive Director and Chairman of the Board of Directors, "Sopharma" AD.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

2017 starts with good news concerning the registration and further development of our product Tabex. The buyer of the share of Sopharma AD in Extab - Achieve - is undertaking a merger with another strong player in the development and registration of innovative medicines - Oncogenex, a publicly traded company on NASDAQ (http://in.reuters.com/article/idINFWN1EV0QP). The procedure is expected to be completed by mid 2017 subject to approval from the US FSC. Sopharma AD will own approximately 3.5% in the newly created company, which will aim at filing the IND for Tabex in 2017.

Apart from the work on Tabex, the new company is also active in the development of other medicines, including one to facilitate the process of treating certain types of cancer.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

2016-12-27, 10:14 Buy 1 000 2.9300

2016-12-27, 10:19 Buy 15 2.9300

2016-12-27, 10:19 Buy 495 2.9350

2016-12-27, 14:46 Buy 90 2.9890

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

2016-12-22 08:10 Buy 3 000 2.9350

2016-12-22 08:12 Buy 2 000 2.9350

2016-12-22 08:15 Buy 5 000 2.9350

2016-12-22 08:25 Buy 5 000 2.9350

2016-12-22 08:31 Buy 3 500 2.9350

2016-12-22 08:41 Buy 1 500 2.9350

2016-12-22 08:50 Buy 5 000 2.9400

2016-12-22 08:59 Buy 5 000 2.9350

2016-12-22 09:04 Buy 927 2.9350

2016-12-22 09:04 Buy 1 073 2.9400

2016-12-22 09:06 Buy 1 000 2.9400

2016-12-22 10:07 Buy 927 2.9400

2016-12-22 10:07 Buy 73 2.9450

2016-12-22 13:23 Buy 226 2.9350

2016-12-23 11:42 Buy 200 2.9440

2016-12-23 12:20 Buy 274 2.9440

2016-12-23 12:36 Buy 300 2.9300

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

"Sopharma" AD (the Company) announces that it was notified by "Sopharma Trading" AD related to Ognian Ivanov Donev, that "Sopharma Trading" AD executed the following transactions related to shares in the Company:

Date and time of the transaction Operation Number of shares Unit price (BGN)

22.12.2016 10:10 Sale 3 000 2.9350

22.12.2016 10:12 Sale 2 000 2.9350

22.12.2016 10:15 Sale 5 000 2.9350

22.12.2016 10:25 Sale 5 000 2.9350

22.12.2016 10:30 Sale 900 2.9300

22.12.2016 10:31 Sale 3 500 2.9350

22.12.2016 10:41 Sale 1 500 2.9350

22.12.2016 10:45 Sale 500 2.9450

22.12.2016 10:50 Sale 5 000 2.9400

22.12.2016 10:59 Sale 5 000 2.9350

22.12.2016 11:04 Sale 927 2.9350

22.12.2016 11:04 Sale 1 073 2.9400

22.12.2016 11:06 Sale 1 000 2.9400

22.12.2016 11:07 Sale 100 2.9400

22.12.2016 12:07 Sale 927 2.9400

22.12.2016 12:07 Sale 73 2.9450

22.12.2016 15:21 Sale 201 2.9350

22.12.2016 15:23 Sale 226 2.9350

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

"Sopharma" AD (the Company) announces that it was notified by "Sopharma Trading" AD related to Ognian Ivanov Donev, that "Sopharma Trading" AD executed the following transactions related to shares in the Company:

Date and time of the transaction Operation Number of shares Unit price (BGN)

19.12.2016 12:24 Sale 1 000 2.9200

19.12.2016 12:25 Sale 500 2.9200

19.12.2016 12:33 Sale 150 2.9220

19.12.2016 12:33 Sale 2 000 2.9200

19.12.2016 12:33 Sale 2 500 2.9200

19.12.2016 12:34 Sale 350 2.9200

19.12.2016 12:42 Sale 3 000 2.9200

19.12.2016 13:15 Sale 400 2.9350

19.12.2016 14:21 Sale 600 2.9350

19.12.2016 14:27 Sale 3 000 2.9200

19.12.2016 14:27 Sale 210 2.9200

19.12.2016 16:52 Sale 250 2.9160

19.12.2016 16:52 Sale 150 2.9160

19.12.2016 16:52 Sale 1 402 2.9150

19.12.2016 16:52 Sale 5 000 2.9150

19.12.2016 16:52 Sale 1 698 2.9150

20.12.2016 10:36 Sale 3 000 2.9200

20.12.2016 10:47 Sale 1 100 2.9200

20.12.2016 12:48 Sale 3 000 2.9300

20.12.2016 12:50 Sale 2 000 2.9300

20.12.2016 13:01 Sale 5 000 2.9300

20.12.2016 14:10 Sale 270 2.9400

20.12.2016 16:45 Sale 730 2.9400

21.12.2016 12:52 Sale 1 000 2.9450

21.12.2016 12:52 Sale 613 2.9450

21.12.2016 13:11 Sale 250 2.9450

21.12.2016 13:33 Sale 137 2.9450

21.12.2016 15:52 Sale 103 2.9400

21.12.2016 15:55 Sale 270 2.9400

21.12.2016 16:34 Sale 400 2.9350

21.12.2016 16:34 Sale 300 2.9360

21.12.2016 16:35 Sale 4 000 2.9350

21.12.2016 16:36 Sale 300 2.9350

21.12.2016 16:39 Sale 5 000 2.9350

21.12.2016 16:41 Sale 700 2.9350

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

2016-12-19 08:30 Buy 359 2.9150

2016-12-19 10:24 Buy 1 000 2.9200

2016-12-19 10:25 Buy 500 2.9200

2016-12-19 10:33 Buy 2 500 2.9200

2016-12-19 10:42 Buy 3 000 2.9200

2016-12-19 12:47 Buy 3 000 2.9200

2016-12-19 13:49 Buy 243 2.9150

2016-12-19 13:52 Buy 700 2.9150

2016-12-19 14:52 Buy 5 000 2.9150

2016-12-19 14:52 Buy 1 698 2.9150

2016-12-19 15:00 Buy 295 2.9300

2016-12-19 15:00 Buy 205 2.9300

2016-12-20 08:17 Buy 5 000 2.9100

2016-12-20 08:23 Buy 4 000 2.9100

2016-12-20 08:36 Buy 3 000 2.9200

2016-12-20 10:48 Buy 3 000 2.9300

2016-12-20 11:01 Buy 5 000 2.9300

2016-12-20 12:10 Buy 230 2.9390

2016-12-20 12:10 Buy 270 2.9400

2016-12-20 14:45 Buy 730 2.9400

2016-12-20 15:00 Buy 705 2.9490

2016-12-20 15:00 Buy 231 2.9490

2016-12-20 15:00 Buy 64 2.9490

2016-12-21 08:15 Buy 557 2.9490

2016-12-21 08:27 Buy 2 000 2.9500

2016-12-21 08:28 Buy 2 000 2.9500

2016-12-21 08:29 Buy 2 000 2.9500

2016-12-21 08:33 Buy 1 000 2.9500

2016-12-21 08:51 Buy 100 2.9500

2016-12-21 10:52 Buy 1 000 2.9450

2016-12-21 10:52 Buy 613 2.9450

2016-12-21 14:35 Buy 400 2.9350

2016-12-21 14:36 Buy 300 2.9350

2016-12-21 14:39 Buy 5 000 2.9350

2016-12-21 14:41 Buy 700 2.9350

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

"Sopharma" AD (the Company) announces that it was notified by "Sopharma Trading" AD related to Ognian Ivanov Donev, that "Sopharma Trading" AD executed the following transactions related to shares in the Company:

Date and time of the settlement Operation Number of shares Unit price (BGN)

2016-12-14 Sale 70 2.9850

2016-12-15 Sale 3 000 2.9800

2016-12-16 Sale 1 379 2.9500

2016-12-16 Sale 1 000 2.9500

2016-12-16 Sale 621 2.9500

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:

Date and time of the settlement Operation Number of shares Unit price (BGN)

2016-12-15 Buy 1000 2.990

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

2016-12-15 08:47 Buy 3 000 2.9800

2016-12-15 08:53 Buy 1 000 2.9600

2016-12-15 13:14 Buy 865 2.9600

2016-12-15 13:50 Buy 135 2.9600

2016-12-15 14:40 Buy 1 000 2.9570

2016-12-15 14:40 Buy 1 449 2.9550

2016-12-15 14:40 Buy 551 2.9550

2016-12-15 14:40 Buy 3 000 2.9500

2016-12-15 14:42 Buy 2 000 2.9200

2016-12-15 14:43 Buy 800 2.9150

2016-12-15 14:44 Buy 1 200 2.9150

2016-12-15 14:45 Buy 358 2.9150

2016-12-15 14:50 Buy 297 2.9600

2016-12-16 08:15 Buy 220 2.9730

2016-12-16 08:49 Buy 150 2.9510

2016-12-16 09:21 Buy 290 2.9510

2016-12-16 10:43 Buy 500 2.9530

2016-12-16 10:43 Buy 560 2.9510

2016-12-16 10:43 Buy 401 2.9500

2016-12-16 11:10 Buy 1 000 2.9500

2016-12-16 12:47 Buy 1 379 2.9500

2016-12-16 13:31 Buy 1 000 2.9500

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

"Sopharma" AD (the Company) announces that it was notified by "Sopharma Trading" AD related to Ognian Ivanov Donev, that "Sopharma Trading" AD executed the following transactions related to shares in the Company:

Date and time of the settlement Operation Number of shares Unit price (BGN)

2016-12-15 Sale 3 000 2.9800

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:

Date and time of the the transaction Operation Number of shares Unit price (BGN)

2016-12-13 Buy 1000 2.995

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:

Date and time of the transaction Operation Number of shares Unit price (BGN)

12.12.2016 Sale 2500 3.000

13.12.2016 Sale 500 2.992

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the transaction Operation Number of shares Unit price (BGN)

2016-12-12 08:43 Buy 1 000 2.9900

2016-12-12 09:44 Buy 240 3.0000

2016-12-12 09:50 Buy 2 500 3.0000

2016-12-12 09:50 Buy 240 3.0000

2016-12-12 09:50 Buy 193 3.0000

2016-12-12 10:47 Buy 240 3.0000

2016-12-12 10:47 Buy 2 760 3.0000

2016-12-12 11:26 Buy 240 3.0000

2016-12-12 11:26 Buy 520 3.0000

2016-12-12 11:26 Buy 240 3.0000

2016-12-12 11:49 Buy 1 520 3.0000

2016-12-12 11:49 Buy 480 3.0000

2016-12-12 11:52 Buy 2 000 2.9800

2016-12-12 11:56 Buy 1 000 2.9800

2016-12-12 12:43 Buy 1 000 2.9800

2016-12-12 12:53 Buy 350 2.9800

2016-12-12 13:18 Buy 250 2.9990

2016-12-12 13:18 Buy 250 2.9990

2016-12-12 13:18 Buy 150 2.9990

2016-12-12 13:19 Buy 44 2.9800

2016-12-12 14:41 Buy 80 2.9990

2016-12-12 14:41 Buy 100 2.9990

2016-12-12 14:41 Buy 320 2.9990

2016-12-13 08:34 Buy 1 000 2.9950

2016-12-13 08:48 Buy 260 2.9990

2016-12-13 08:48 Buy 250 2.9990

2016-12-13 08:48 Buy 490 2.9990

2016-12-13 10:09 Buy 2 000 2.9950

2016-12-13 10:14 Buy 456 2.9980

2016-12-13 10:22 Buy 4 282 2.9980

2016-12-13 10:22 Buy 718 2.9980

2016-12-13 14:04 Buy 500 2.9920

2016-12-13 14:05 Buy 500 2.9920

2016-12-13 14:26 Buy 268 2.9940

2016-12-13 14:26 Buy 732 2.9970

2016-12-13 14:30 Buy 1 000 2.9970

2016-12-13 14:30 Buy 747 2.9970

2016-12-13 14:30 Buy 253 2.9970

2016-12-13 14:47 Buy 800 2.9900

2016-12-13 14:52 Buy 1 640 2.9800

2016-12-13 14:53 Buy 95 2.9800

2016-12-14 08:13 Buy 1 465 2.9900

2016-12-14 08:25 Buy 1 000 2.9800

2016-12-14 08:27 Buy 300 2.9800

2016-12-14 08:28 Buy 250 2.9800

2016-12-14 08:52 Buy 450 2.9800

2016-12-14 08:58 Buy 185 2.9700

2016-12-14 09:46 Buy 1 800 2.9700

2016-12-14 10:18 Buy 985 2.9700

2016-12-14 10:18 Buy 15 2.9700

2016-12-14 11:04 Buy 140 2.9700

2016-12-14 11:19 Buy 520 2.9700

2016-12-12 08:43 Buy 200 2.9700

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD (the "Company") hereby notifies that on 14 December 2016 Sopharma AD filed with the Financial Supervision Commission a tender offering for the shares of all other shareholders in Unipharm AD.

Sopharma AD as a offeree states that it does not own 1 342 234 shares, representing 22.37% from the total number of sahres with ISIN BG1100154076 and from the votes in the general meeting of Unipharm AD and files the tender offering to the remaining sahreholders owning ordinary shares of Unipharma AD for the purchase of those shares.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:

Date and time of the settlement Operation Number of shares Unit price (BGN)

2016-12-14 Buy 1000 2.980

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

"Sopharma" AD (the Company) announces that it was notified by "Donev Investments Holding" AD related to Ognian Ivanov Donev, that "Donev Investments Holding" AD executed the following transactions related to shares in the Company:

Date and time of the settlement Operation Number of shares Unit price (BGN)

2016-12-12 Buy 1000 2.985

2016-12-13 Buy 3000 2.990

2016-12-13 Buy 46 2.990

2016-12-13 Buy 454 2.990

2016-12-13 Buy 1500 2.990

2016-12-13 Buy 1600 2.990

2016-12-13 Buy 3000 2.990

2016-12-13 Buy 3000 2.990

2016-12-13 Buy 250 2.995

2016-12-13 Buy 7 2.995

2016-12-13 Buy 143 2.997

2016-12-13 Buy 500 2.997

2016-12-13 Buy 357 2.997

2016-12-13 Buy 143 2.997

2016-12-13 Buy 357 2.997

2016-12-13 Buy 325 2.998

2016-12-13 Buy 450 2.998

2016-12-13 Buy 406 3.000

2016-12-13 Buy 500 3.005

2016-12-13 Buy 80 3.000

2016-12-13 Buy 500 3.010

2016-12-13 Buy 220 3.000

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time(UTC) of the settlement Operation Number of shares Unit price (BGN)

2016-12-08 08:28 Buy 3 000 2.9890

2016-12-08 08:33 Buy 840 2.9700

2016-12-08 08:36 Buy 2 000 2.9900

2016-12-08 08:49 Buy 180 2.9900

2016-12-08 08:49 Buy 1 000 2.9900

2016-12-08 08:49 Buy 1 980 2.9900

2016-12-08 08:50 Buy 3 000 2.9900

2016-12-08 08:50 Buy 2 980 2.9900

2016-12-08 08:50 Buy 20 2.9900

2016-12-08 08:54 Buy 280 2.9900

2016-12-08 08:54 Buy 720 2.9900

2016-12-08 09:00 Buy 2 000 2.9900

2016-12-08 09:01 Buy 1 950 2.9900

2016-12-08 09:01 Buy 1 050 2.9900

2016-12-08 09:05 Buy 3 000 2.9900

2016-12-08 09:06 Buy 2 000 2.9900

2016-12-08 09:13 Buy 3 000 2.9900

2016-12-09 09:16 Buy 1 000 3.0100

2016-12-09 09:21 Buy 1 000 3.0150

2016-12-09 11:29 Buy 835 3.0150

2016-12-09 11:29 Buy 165 3.0150

2016-12-09 13:26 Buy 1 000 3.0000

2016-12-09 13:29 Buy 1 000 2.9900

2016-12-09 13:42 Buy 1 087 2.9850

2016-12-09 13:51 Buy 40 2.9850

2016-12-09 14:39 Buy 1 400 2.9850

2016-12-09 14:54 Buy 300 3.0000

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

"Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:

Date and time of settlement Operation Number of shares Unit price (BGN)

12.12.2016 Sale 399 2.9900

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

"Sopharma" AD (the Company) announces that it was notified by "Sopharma Trading" AD related to Ognian Ivanov Donev, that "Sopharma Trading" AD executed the following transactions related to shares in the Company:

Date and time of the settlement Operation Number of shares Unit price (BGN)

12.12.2016 Sale 3 000 2.9900

12.12.2016 Sale 143 2.9970

12.12.2016 Sale 357 2.9970

12.12.2016 Sale 500 3.0050

12.12.2016 Sale 500 3.0050

12.12.2016 Sale 250 3.0010

12.12.2016 Sale 1 550 3.0000

12.12.2016 Sale 200 3.0000

12.12.2016 Sale 500 3.0100

13.12.2016 Sale 1 000 3.0100

13.12.2016 Sale 1 000 3.0150

13.12.2016 Sale 165 3.0150

13.12.2016 Sale 835 3.0150

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

"Sopharma" AD (the Company) announces that it was notified by "Elpharma" AD related to Ognian Ivanov Donev, that "Elpharma" AD executed the following transactions related to shares in the Company:

Date and time of settlement Operation Number of shares Unit price (BGN)

09.12.2016 Sale 5000 2.9770

09.12.2016 Sale 1000 2.9550

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time of the settlement Operation Number of shares Unit price (BGN)

09.08.2016 Buy 365 2.9740

09.08.2016 Buy 123 2.9740

09.08.2016 Buy 82 2.9750

09.08.2016 Buy 430 2.9770

09.08.2016 Buy 365 2.9770

09.08.2016 Buy 5 000 2.9770

09.08.2016 Buy 415 2.9770

09.08.2016 Buy 410 2.9770

09.08.2016 Buy 175 2.9770

09.08.2016 Buy 635 2.9850

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

Sopharma AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that the company ELPHARMA related to him, executed the following transactions related to shares of the Company:

Date and time of settlement Operation Number of shares Unit price (BGN)

5.12.2016 Sale 4 000 2.9700

5.12.2016 Sale 450 2.9700

5.12.2016 Sale 500 2.9700

5.12.2016 Sale 50 2.9700

6.12.2016 Sale 520 2.9900

6.12.2016 Sale 81 2.9900

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

Sopharma AD announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that the company "Donev Investments Holding AD" related to him, executed the following transactions related to shares in the Company:

Date and time of the settlement Operation Number of shares Unit price (BGN)

05.12.2016 Buy 310 2.989

05.12.2016 Buy 720 2.996

05.12.2016 Buy 2000 2.998

05.12.2016 Buy 2601 2.990

05.12.2016 Buy 399 2.990

05.12.2016 Buy 2000 2.968

06.12.2016 Buy 1000 2.960

06.12.2016 Buy 316 2.980

06.12.2016 Buy 684 2.989

06.12.2016 Buy 924 2.980

06.12.2016 Buy 476 2.989

06.12.2016 Buy 600 2.989

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date and time of the settlement Operation Number of shares Unit price (BGN)

5.12.2016 Buy 4 940 3.0000

5.12.2016 Buy 60 3.0000

5.12.2016 Buy 5 000 3.0000

5.12.2016 Buy 8 000 2.9900

5.12.2016 Buy 2 821 2.9800

5.12.2016 Buy 4 179 2.9900

5.12.2016 Buy 1 250 2.9750

5.12.2016 Buy 750 2.9750

5.12.2016 Buy 740 2.9700

5.12.2016 Buy 4 000 2.9700

5.12.2016 Buy 2 000 2.9700

5.12.2016 Buy 260 2.9700

5.12.2016 Buy 4 000 2.9700

5.12.2016 Buy 860 2.9700

5.12.2016 Buy 1 140 2.9700

6.12.2016 Buy 1 161 2.9450

6.12.2016 Buy 1 000 2.9550

6.12.2016 Buy 1 000 2.9600

6.12.2016 Buy 180 2.9800

6.12.2016 Buy 558 2.9890

6.12.2016 Buy 81 2.9900

6.12.2016 Buy 520 2.9900

6.12.2016 Buy 500 2.9800

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

For the first eleven months of this year, revenues from sales decreased by 5% compared to the same period of 2015, including 2% increase of domestic sales and 10% decrease of export sales. "The Russian market remains uncertain, which does not allow us to make forecasts for the year-end sales results, but we managed to limit the decrease of sales revenues in the second half of 2016.", states Ognian Donev, PhD, Executive Director and Chairman of the Board of Directors of Sopharma AD.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

CONSOLIDATED FINANCIAL STATEMENTS FOR Q3 2016

1. Financial Statements

2. Notes to the Financial Statements

3. Management report

4. Templates of the financial reports approved by the Bulgarian FSC

5. Declaration

6. Additional information

7. Annex 9

8. List of insider information

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD (the "Company") announces that on 18 November 2016 the Company received a notification for the acquisition of 505 364 shares, representing 0.37% of its capital, by ZUPF Allianz Bulgaria. After the transaction the share of ZUPF Allianz Bulgaria in the capital of Sopharma AD reached 5.17%.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD (the "Company") announces that on 16 November 2016 the Company received a notification for the sale of 342 680 shares, representing 0.25% of its capital, by ZUPF Allianz Bulgaria. After the transaction the share of ZUPF Allianz Bulgaria in the capital of Sopharma AD reached 4.80%.

The date of the registration of the transaction with the Central Depository is 11 November 2016.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

Sopharma AD hereby notifies that following a decision of the Board of directors as of the moment Sopharma AD has acquired a total of 68% of the capital of Veta Pharma AD.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

The Board of Directors of Sopharma AD decided to purchase up to 100% of the capital of "Veta Pharma" AD for a price not exceeding 2.12 BGN per share. The Board authorised the Executive Director to undertake all necessary legal actions thereby.

"Veta Pharma" AD is a modern and dynamic Bulgarian pharmaceutical porducer of 47 different products divided in three categories: medicinal products, food additives and cosmetic products. The volume of sales for 2015 exceeds 3 million packages on the Bulgarian pharmaceutical market. 50 people work at the company.

"Veta Pharma" AD plans, produces and distributes its products in accordance with the Good Manufacturing Practice (GMP) and the standards applied by the Bulgarian and European legal framewok.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

For the first ten months of this year, revenues from sales decreased by 6% compared to the same period of 2015, including 1% increase of domestic sales and 11% decrease of export sales.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.

INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDING 30 SEPTEMBER 2016

1. Financial Statements

2. Notes to the Financial Statements

3. Management report

4. Templates of the financial reports approved by the Bulgarian FSC

5. Declaration

6. Insider Information

7. Additional Information

8. List of insider information

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

SOPHARMA AD hereby informs that in accordance with its transparency policy and led by the internationally accepted best practices in the area of corporate governance Sopharma AD will continue to publish its individual and consolidated quarterly financial statements in full in service of its shareholders and the investment community.

We also notify that the company now publishes all regulated information on the web site www.sopharmagroup.eu - the new website of Sopharma Group.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

Sopharma AD (the "Company") announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that the company ELPHARMA related to him, executed the following transactions related to shares of the Company:

Date and time of settlement Operation Number of shares Unit price (BGN)

29.9.2016 Sale 2 000 2.8480

30.9.2016 Sale 2 371 2.9300

30.9.2016 Sale 2 629 2.9300

30.9.2016 Sale 1 000 2.9450

30.9.2016 Sale 204 2.9450

30.9.2016 Sale 1 500 2.9450

30.9.2016 Sale 296 2.9450

30.9.2016 Sale 2 000 2.9900

3.10.2016 Sale 10 3.0400

3.10.2016 Sale 990 3.0400

3.10.2016 Sale 1 030 3.0550

3.10.2016 Sale 970 3.0550

3.10.2016 Sale 1 000 3.0550

3.10.2016 Sale 1 893 3.0550

3.10.2016 Sale 3 000 2.9700

3.10.2016 Sale 150 2.9700

3.10.2016 Sale 3 400 2.9700

3.10.2016 Sale 1 450 2.9700

3.10.2016 Sale 1 450 2.9700

3.10.2016 Sale 1 550 2.9700

3.10.2016 Sale 3 000 2.9700

3.10.2016 Sale 270 2.9620

3.10.2016 Sale 341 2.9630

3.10.2016 Sale 341 2.9630

3.10.2016 Sale 341 2.9630

3.10.2016 Sale 341 2.9630

3.10.2016 Sale 295 2.9630

3.10.2016 Sale 71 2.9630

4.10.2016 Sale 2 000 2.9600

4.10.2016 Sale 3 400 2.9550

4.10.2016 Sale 240 2.9550

4.10.2016 Sale 306 2.9550

The transfer of the above-mentioned shares was executed on the Bulgarian Stock Exchange in Sofia (regulated market) by way of electronic trade.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

In accordance with the provisions of art. 27, para 3 from Ordinance 2 on the prospectuses Sopharma AD and due to change in the internet address of the corporate website of the company, Sopharma hereby advises that the company published and disseminated information to the public in the last 12 months in the Republic of Bulgaria and in other member states in the following ways:

1. Through the unified information system of the Bulgarian Stock Exchange E-register - www.fsc.bg;

2. Through X3news information agency - http://www.x3news.com;

3. Through the electroinc media Investor.bg - www.investor.bg;

4. Through Infostock bulletin - www.infostock.bg/;

5. Through the internet web site of the company - http://www.sopharmagroup.bg ;

http://www.sopharmagroup.com

http://www.sopharmagroup.net

http://www.sopharmagroup.eu

6. Through the Polish Financial Supervision Commission system ESPI;

7. Through the Polish Press Agency - www.pap.pl

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

SOPHARMA AD hereby informs that as a result of its intention to express interest in acquiring a commercial company operating on the territory of the Republic of Moldova, as a first step Sopharma AD filed a request for approval of concentration with the competent authorities in the Republic of Moldova.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

We would like to notify that Board of directors of Sopharma AD discussed a proposal filed by Homogen AD on October 4, 2016 for the sale of shares from the capital of Veta Farma AD. The Board of directors of Sopharma AD authorizes the Executive director to negotiate with representatives of the seller.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 17. 1 MAR.

For the first nine months of this year, revenues from sales decreased by 3% compared to the same period of 2015, including 1% increase of domestic sales and a 5% decrease of export sales. "We are witnessing a positive trend in September, but it is hard to forecast whether it will be stable. However, we managed to a certain extent to compensate the weaker performance of the Russian market in the first half of this year.", comments Ognian Donev, PhD, Chariman of the Board of Directors and Executive director of Sopharma AD.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz

Podstawa prawna: art. 19. 3 MAR.

SOPHARMA AD hereby informs that from 29 September 2016 up to and including 30 September 2016 the Company bought 57 328 own shares representing 0.027% of the share capital of the Company, at a total value of 171 228.54 BGN on the Bulgarian Stock Exchange, the average price per share was 2.99 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 662 414, representing 4.20% of the share capital of the Company.

Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1

kom espi zdz